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The ubiquitin proteasome system in Huntington disease





Neurodegenerative diseases are characterized by progressive dysfunction of the 
nervous system. These devastating illnesses commonly correlate with atrophy 
of the affected areas in the brain or peripheral nervous system. Several of these 
disorders including Alzheimer disease (AD), amyotropic lateral sclerosis (ALS) and 
Parkinson disease (PD) are sporadic although some familial forms are caused by gene 
mutations. 
The polyglutamine diseases consist of a family of neurodegenerative disorders that are 
caused by the excessive expansion of a CAG repeat in a transcribed gene. Consecutive 
translation of this CAG repeat results in the formation of proteins containing a 
pathological polyglutamine repeat. To date, nine disorders have been identified with 
polyglutamine expansions in different proteins that correspond with distinct clinical 
presentation (Table 1). In all these diseases an inverse correlation is found between 
polyglutamine expansion and age of disease onset.
Huntington Disease (HD) is the best known and most extensively studied of the 
polyglutamine diseases with an incidence of one in every 10-20,000 inhabitants of the 
western world. This accounts for an estimated 1300 HD patients in the Netherlands 
and even more people that are currently at risk. The huntingtin protein (Htt) – encoded 
by the HTT gene – functions in vesicle transport and normally contains between 6 
and 27 glutamine repeats. Persons with over 36 consecutive glutamines in Htt, usually 
develop HD around midlife. An intermediate repeat length between 36 and 39 results 
in disease development in some people whereas others are spared (McNeil et al., 1997; 
Rubinsztein et al., 1996; Zoghbi and Orr, 2000). Although there is a clear correlation 
between longer polyglutamine repeat lengths and earlier disease onset, patients with 
equal pathological expansion display enormous variation in clinical manifestation 
and a clear disparity between repeat length and subcortical atrophy (Halliday et al., 
1998). Apparently, other factors, including genetic modifiers such as the wild-type 
HTT allele can influence development of the polyglutamine diseases by modifying 
the mutant protein toxicity (Aziz et al., 2009; Wexler et al., 2004). These differences 
indicate that cellular mechanisms modulate the neurotoxic properties of the mutant 
Htt protein. 
The striatum and frontal cortex are the areas most affected in HD demonstrating 
obvious pathology. Especially the medium spiny neurons of the striatum are affected 
and most of these neurons are lost over the course of the disease. Within the remaining 
striatal neurons, neuronal intranuclear inclusions (NII) are identified that contain 
the mutant Htt protein. In addition to the NII several dystrophic neurites have been 
identified that resemble axonal processes (DiFiglia et al., 1997). Large polyglutamine 
expansions to more than 55 sometimes arise de novo that cause a juvenile form of the 
disease, which in general starts before the age of 20 years, causes more widespread 

































































































































































































































































































































































































































































































































































































































































polyglutamine repeat lowers the threshold for toxicity of the expanded protein. As a 
result, different neuronal populations with lower expression levels become affected by 
the aberrant protein.
The spinocerebellar ataxias (SCAs) comprise a heterogeneous group of disorders that 
share cerebellar atrophy and variable degeneration of brain stem and spinal cord. The 
gene products of SCA1, 2, 3 and 7 all encode proteins with diverse cellular functions 
(Table 1). SCA17 which was most recently discovered, contains an expansion in the 
TATA-binding protein (TBP) a general transcription initiation factor (Nakamura et 
al., 2001). Affected regions of the SCAs include the cerebellum and spinal cord with 
additional affected areas depending on the expanded gene as listed in Table 1. In the 
channelopathy SCA6, neurodegeneration is caused by a small CAG expansion (to 19-
30 repeats) in a calcium channel subunit that presumably causes a change of function 
(Zhuchenko et al., 1997). In contrast, the other eight polyglutamine diseases are 
characterized by a gain of function mechanism whereby the expanded polyglutamine 
repeat acquires a toxic conformation (Scherzinger et al., 1997). Nonetheless, loss of 
the functional protein in addition to expression levels possibly contributes to the 
tissue specific distribution and phenotype of the disease. 
Spinobulbar muscular atrophy (SBMA) is the only polyglutamine disease that shows 
an X-linked pattern of inheritance in contrast to the autosomal dominant inheritance 
of the other diseases (Kennedy et al., 1968). The CAG repeat is located in the androgen 
receptor, a steroid hormone receptor that activates transcription upon binding of 
androgen. Dentatorubropallidoluysian atrophy (DRPLA) in turn, is caused by a 
polyglutamine expansion in the atrophin-1 protein that is widely expressed and thus 
causes a more extensive pathology (Koide et al., 1994).
In addition to the polyglutamine expansion disorders several triplet repeat diseases 
exist that are caused by repeat expansion in non-transcribed regions. These diseases 
also display autosomal dominant inheritance and include SCA8 and 12 as well as 
Friedreich ataxia (reviewed in (Everett and Wood, 2004)). Repeat expansion in these 
disorders results in disruption of gene expression causing the disease symptoms. In 
contrast to the polyglutamine expansion disorders these are not represented by a toxic 
gain of function mechanism that results in neuronal toxicity. 
Since the discovery of the mutation responsible for HD, extensive research has been 
performed using genetic models in cell-lines as well as transgenic animals. These model 
systems have resulted in many findings that have lead to a better understanding of 
human disease in HD and other polyglutamine diseases. This review will summarize 
several of the important aspects leading to neurodegeneration in HD with a specific 
focus on the ubiquitin proteasome system (UPS). 
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HD animal models 
Animal models are being used extensively to gain a better insight in the characteristics 
of genes and disorders and study early disease development. Over the past years several 
HD mouse models were made that show some resemblance to the characteristics of 
human disease (Heng et al., 2008). These transgenic animals have enabled the study 
of cells in their physiological context as well as early events in the development of HD. 
The R6/2 transgenic line contains the first exon of HTT with a repeat expansion of 144 
CAG and is the most extensively studied model (Mangiarini et al., 1996). These mice 
display a very rapid disease progression with severe atrophy which is however not 
selective for regions affected in HD. R6/1 mice display similar characteristics although 
slower disease progression due to lower expression levels of mutant HTT and a repeat 
of 116 CAG. N171-82Q transgenic mice contain not only the first but also the second 
exon of Htt with 82 glutamines and display a less severe phenotype which includes 
striatal atrophy (Schilling et al., 1999). 
In contrast, the YAC128 mice contain the full length HTT construct with a repeat of 
120 CAGs under the endogenous promoter. Consequently, this model does show a 
better representation of HD with comparable regional brain atrophy (Van Raamsdonk 
et al., 2005). The same accounts for the HdhQ94, HdhQ111, HdhQ140 and Hdh(CAG)150 
knock in mice that contain an expanded CAG repeat within the endogenous mouse 
HTT gene ranging from 94 to 150 repeats (Menalled et al., 2002). Similarly, the 
BACHD transgenic mice show a significantly delayed onset of neurodegenerative 
signs and may be a better model for HD compared to R6/2 (Gray et al., 2008).
Further transgenic models have been developed in other organisms that might 
more closely mimic human disease development in HD. A transgenic rat model has 
been generated that contains a large rat HTT fragment with a moderate repeat of 51 
CAG (von Horsten et al., 2003). These rats resemble human HD with late-onset and 
progressive phenotype which includes cognitive impairment and motor dysfunction. 
Neuropathology includes the formation of NII and striatal shrinkage. A transgenic 
HD model in a rhesus macaque is currently being developed containing exon 1 of 
HTT with 84 CAG repeats (Yang et al., 2008). These monkeys demonstrate clinical HD 
features including dystonia and chorea. Neuropathology includes NII and neuropil 
aggregates and early death in monkeys carrying higher copy numbers.
The mouse homolog of HTT is essential during early development and null-mice 
that lack functional Htt die at embryonic day 7.5 (Duyao et al., 1995; Nasir et al., 
1995; Zeitlin et al., 1995). Conditional knock-down of HTT results in progressive 
neurodegeneration demonstrating an important function of Htt also in the adult 
brain (Dragatsis et al., 2000). In contrast, knock-down of HTT in Drosophila does 
not affect viability although long term survival and mobility are affected (Zhang et 
al., 2009). However, loss of Drosophila HTT does result in decreased complexity 
of axonal termini and increased susceptibility of animals to mutant Htt expression. 
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Altogether, these data indicate an important function of Htt in development and 
neuroprotection and indicates that loss of normal Htt function possibly contributes 
to specific neuropathology. 
Protease cleavage
In HD, nuclear inclusions consist primarily of N-terminal fragments of mutant Htt. 
Nuclear translocation potentially requires processing of the full length 348 kDa protein 
into smaller fragments in order to enter the nucleus. Caspase cleavage of wild type 
and mutant Htt at position 552 occurs in vivo before the onset of neurodegeneration 
(Wellington et al., 2002). Indeed, in transgenic mice, caspase-6-mediated cleavage of 
Htt is required for the onset of neuronal dysfunction (Graham et al., 2006). Within the 
NII even smaller fragments are detected suggesting further processing of the mutant 
protein before translocation. Small fragments arise from cleavage at position 167 
resulting in an N-terminal fragment that exerts increased aggregation and toxicity 
(Ratovitski et al., 2009). 
Nuclear translocation
Despite the diverse functions of the polyglutamine proteins in the cytoplasm and the 
nucleus, all polyglutamine expansion disorders are represented by nuclear inclusions. 
Toxicity of expanded polyglutamine proteins is increased upon translocation to 
the nucleus supporting an important contribution of the intracellular location to 
pathogenesis (Peters et al., 1999; Saudou et al., 1998). Potentially, deregulation of 
transcription factors is responsible for the increased toxicity of nuclear expanded 
polyglutamine protein. The X-linked recessive inheritance of SBMA supports this 
notion as the androgen receptor is translocated to the nucleus upon binding of 
testosterone. Also in SBMA transgenic mice, neuronal dysfunction is specific for males 
but can be induced in females by administration of testosterone whereas castration 
rescues motor neuron deficits in males (Chevalier-Larsen et al., 2004). 
Changing the intracellular localization of other polyglutamine proteins similarly affects 
the toxicity of mutant proteins demonstrating a clear influence of compartmental 
interactions (Nucifora et al., 2003; Peters et al., 1999). In vivo, inactivation of the 
nuclear localization signal in ataxin-1 resulted in decreased Purkinje cell pathology 
and these mice did not demonstrate significant motor abnormalities (Klement et al., 
1998). Additional nuclear targeting of mutant Htt resulted in comparable degeneration 
demonstrating that the disturbance of nuclear mechanisms accounts for an important 
part of the neuropathology (Schilling et al., 2004). These results demonstrate that 





One aspect of the toxic gain of function of mutant Htt is thought to be linked to 
deregulation of gene expression in neurons. A wide array of transcription changes has 
been detected in HD mouse models that show some overlap but are in part specific 
for each model (Chan et al., 2002; Luthi-Carter et al., 2002; Luthi-Carter et al., 2000; 
Luthi-Carter et al., 2002; Sipione et al., 2002). Nevertheless, these studies clearly 
demonstrate the effect of expanded Htt on gene expression in HD models. In human 
HD brain, the transcriptional changes parallel the pathology of HD with more severe 
changes in the caudate nucleus followed by the cortex (Hodges et al., 2006). mRNA 
changes are observed in very diverse pathways that range from neuronal signalling 
and neurotransmitter receptors to homeostasis and ion channels. 
Expanded Htt has been shown to have a stronger affinity for binding directly to 
DNA and will thereby prevent the binding of transcription factors to the promoters 
(Benn et al., 2008). Additionally, this direct binding results in a more open chromatin 
structure which also affects transcription. Wild-type Htt has been shown to interact 
with repressor element-1 transcription factor / neuron restrictive silencer factor 
(REST/NRSF) (Zuccato et al., 2003). This interaction is disturbed through expansion 
of the polyglutamine repeat resulting in decreased expression of neuronal genes like 
brain derived neurotrophic factor (BDNF) which contain a neuron restrictive silencer 
element (NRSE). 
In contrast, expansion of the polyglutamine repeat in Htt results in an increased 
interaction with the transcription factor Specificity protein-1 (Sp1) (Li et al., 2002). 
This binding thereby disrupts the normal promoter binding of Sp1 resulting in 
decreased expression of several genes including the D2 dopamine receptor and nerve 
growth factor receptor (NGFR) (Dunah et al., 2002; Li et al., 2002). A schematic 
representation of transcriptional deregulation is given in Figure 1. Overexpression of 
Sp1 partially rescues the toxicity of mutant Htt and the decrease in neurite extension 
demonstrating that these effects are indeed caused by insufficiency of Sp1. In SCA1, 
polyglutamine binding protein-1 (PQBP-1) has been shown to bind mutant ataxin-1 
resulting in decreased phosphorylation of polymerase-II and reduction in basal 
transcription (Okazawa et al., 2002). 
cAMP responsive element binding protein (CREB) and family members (CREM) 
are essential for neuronal development and affect neuronal survival (Mantamadiotis 
et al., 2002). In HD, CREB binding protein (CBP, a histone acetyltransferase) has 
been shown to be partially recruited to NIIs potentially affecting transcription 
regulation. Expansion of the polyglutamine repeat in vitro, results in a reduction of 
CRE mediated transcription and specific toxicity which can partially be rescued by 
cAMP overexpression (Wyttenbach et al., 2001). Besides the histone acetyltransferase 
CBP, other transcriptional co-activators and histone modification enzymes have been 
implicated in transcriptional dysregulation by mutant Htt. These include HDAC4 
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and HDAC6 (Dompierre et al., 2007; Steffan et al., 2001; Thomas et al., 2008), SIRT2 
(Luthi-Carter et al., 2010) and PGC1α (Cui et al., 2006; Strand et al., 2007; Weydt et 
al., 2006).
Furthermore, the TBP transcriptional co-activator TAFII130 has been shown to 
interact directly with expanded polyglutamine repeats (Shimohata et al., 2000). TBP 
is required for CREB- and Sp1-dependent transcriptional activation and TAFII130 
binding to expanded polyglutamines can thereby affect both CRE and Sp1 dependent 
transcriptional activation. In addition to direct interaction TAFII130, CREB, TBP 
and Sp1 have been shown to be recruited to NII thereby affecting the transcription 
regulation. However, in HD mouse models it was shown that these transcription 
factors do not show considerable localization to the NII and in addition normal 
expression levels of the soluble forms were found (Yu et al., 2002). These differences 
in co-localization could be caused by prolonged Htt expression in patients in contrast 
to the short term exposure to extensive repeats in transgenic animals. Also in juvenile 
HD more pronounced aggregate formation is detected that results in a different 
pattern of disease progression. Potentially, interaction of transcription factors with 
soluble Htt has a more profound effect on gene expression in patients.
Figure 1: Transcriptional deregulation in HD.
Htt containing an expanded polyglutamine repeat is misfolded and cleaved into smaller fragments 
that can enter the nucleus. Within the nucleus Htt was shown to interact with several transcription 
factors including CBP, TAFII130 and Sp1. The increased association of mutant huntingtin results 
in deregulation of normal gene transcription.
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Htt function and interactions 
Although disease development is clearly triggered by the expanded polyglutamine 
repeat in Htt, the precise function of Htt is still unknown. Several interaction partners 
have been identified that suggest diverse biological functions of Htt in transcription, 
vesicle transport and neuroprotection. A number of large scale interaction studies have 
also been performed that have yielded many interactors of Htt with little biological 
validation (Goehler et al., 2004; Kaltenbach et al., 2007).
Huntingtin interacting protein 1 (Hip1) interacts with Htt and clathrin coated vesicles 
implicating Htt in vesicle transport. Clathrin binding to Hip1 and Hip1r (Hip1 related) 
reduces the affinity for actin binding, suggesting a role for Hip1 and Hip1r in vesicle 
budding (Wilbur et al., 2008). Expansion of the polyglutamine repeat has been shown 
to reduce the binding of Htt to Hip1 (Kalchman et al., 1997). This reduced interaction 
results in increased levels of available Hip1 which consequently interacts with another 
interaction partner Hip1 protein interactor (Hippi) to recruit caspase-8 and activate 
apoptosis (Gervais et al., 2002). In addition, this interaction results in increased 
translocation of the Hip1/Hippi complex to the nucleus to activate transcription of 
caspase-1 (Banerjee et al., 2010). Consequently, the polyglutamine expansion in Htt 
will indirectly result in increased caspase-1 and -8 dependent apoptosis.
Wild-type Htt functions in vesicle transport by binding to dynactin and motor 
proteins dynein and kinesin. Phosphorylation by Akt at serine 421 (S421) results in 
recruitment of kinesin-1 to the dynactin complex on microtubules and vesicles (Colin 
et al., 2008). This kinesin recruitment promotes anterograde transport of vesicles 
including BDNF cargoes and dephosphorylation results in detachment of kinesin 
and retrograde transport. Additionally, wild-type Htt has been implicated in vesicle 
trafficking of proteins from the Golgi to the extracellular space (Strehlow et al., 2007). 
Accordingly, Htt knock-down results in a downregulation of extracellular proteins 
that are involved in matrix, cell adhesion, receptor binding or hormone activity. 
Mutant Htt was shown to inhibit both anterograde and retrograde fast axonal transport 
without visible aggregates (Szebenyi et al., 2003). Interestingly, both a reduction and 
polyglutamine expansion of Htt in Drosophila resulted in axonal transport defects 
(Gunawardena et al., 2003). Although large axonal aggregates have been detected 
that could directly block vesicle transport these defects are most likely caused by an 
interaction with the motor proteins. This binding of dynein and kinesin to aggregation 
prone Htt could result in depletion of motor proteins resulting in increased stalling 
and axonal accumulation of transport vesicles (Sinadinos et al., 2009). A schematic 
representation of the disturbed vesicle transport is given in Figure 2. More specifically, 
Htt expansion and proteolysis both result in disruption of BDNF vesicular transport 
potentially affecting neurotrophic support through cortico-striatal projections 
(Gauthier et al., 2004). Phosphorylation of S421 of mutant Htt restores both the 
anterograde and retrograde transport of vesicles by normalizing the interaction with 
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p150Glued and microtubules (Zala et al., 2008). Akt or IGF-1 can thereby compensate 
for the transport defect by phosphorylating Htt. 
Huntingtin associated protein 1 (Hap1) has been shown to be responsible specifically 
for transport of BDNF cargoes through interaction with kinesins and p150Glued. 
In addition, amino acid substitution of threonine for methione at position 441 in 
Hap1 results in a delay in the age at onset of HD in human (Metzger et al., 2008). 
The methionine substitution thereby results in tighter binding of Htt to Hap1 and 
reduces soluble Htt which prevents toxicity of the expanded polyglutamine protein. 
The polyglutamine expansion in Htt interferes with the function of Hap1, dynein 
and kinesin and thereby disturbs axonal transport which is essential for normal 
functioning of neurons.
Figure 2: Disturbed microtubule based vesicle transport.
Both a reduction of Htt levels as well as polyglutamine expansion result in disturbed retrograde 
and anterograde vesicle transport. Htt most likely interacts directly with the motor proteins 
dynein and kinesin resulting in depletion of these proteins and increased vesicle stalling. Also 
Hap1 binding is disturbed which results in decreased transport of BDNF vesicles. Tighter binding 
of mutant Hap1T441M results in a delay in the age at onset of HD suggesting that polyglutamine 
expansion disturbs normal binding of Htt to Hap1.
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The neuroprotective effect of Htt can be greatly governed by the indispensable function 
of wild-type Htt in neuronal vesicle transport. In addition, wild-type Htt has been 
shown to inhibit caspase-3 activation in vivo which is disturbed by polyglutamine 
expansion or HTT knock-down (Zhang et al., 2006). P21-activated kinase-2 (Pak2) 
was shown to bind Htt which prevents cleavage of Pak2 by caspase-3 and -8 (Luo and 
Rubinsztein, 2009). The constitutive active C-terminal fragment Pak2-p34 induces 
cell death and is detected in response to different death stimuli. In contrast, Pak1 
interaction with Htt increases oligomerization of both wild-type as well as expanded 
Htt (Luo et al., 2008). This interaction thereby causes an increase in aggregate 
formation of expanded Htt as well as polyglutamine-induced cell death. Altogether, 
these Htt interactions indicate important functions for wild-type Htt and provide 
insight in an additional loss of function due to polyglutamine expansion.
Neurotransmitter trafficking and activity 
Synaptic activity through NMDAR promotes inclusion formation of mutant Htt through 
upregulation of T complex-1 (TCP-1) – part of the chaperonin TCP-1 ring complex 
– and thereby increases survival (Okamoto et al., 2009). Extrasynaptic stimulation of 
NMDAR, including glutamate excitotoxicity increases cell death through upregulation 
of Rhes – a small guanine nucleotide binding protein – and downregulation of CREB 
resulting in lower PGC-1α which is neuroprotective (Cui et al., 2006; Subramaniam 
et al., 2009). A schematic representation of disturbed neurotransmitter activity and 
trafficking is given in Figure 3. Interestingly, this demonstrates that synaptic activity 
ameliorates the toxicity of mutant Htt in addition to increased vulnerability of these 
neurons to excitotoxic insults. Furthermore, a direct interaction has been shown for 
Htt with postsynaptic density protein-95 which interacts with the NR2B subunit of 
NMDAR and this interaction is increased upon repeat expansion (Fan et al., 2009). 
Inhibition of binding to NR2B reduced NMDAR surface expression on medium spiny 
neurons and consequentially the susceptibility to excitotoxicity. 
Inhibitory synaptic transmission is regulated by GABAA receptor density at synapses. 
Trafficking of GABAAR is performed by kinesin family motor protein 5 (Kif5) 
whereby Hap1 functions as adaptor protein for linking Kif5 to the receptor vesicles 
(Twelvetrees et al., 2010). Since mutant Htt demonstrates a stronger affinity for Hap1 
binding compared to wild-type Htt the polyglutamine expansion is likely to interfere 
with normal transport of the receptor vesicles to the synapse. Strikingly, mutation 
of Ubiquitin specific protease-14 causes ataxia and results in increased expression 
of GABAAR at the surface of Purkinje cells increasing inhibitory signalling which 
disrupts normal motor coordination (Lappe-Siefke et al., 2009; Wilson et al., 2002). 
These findings underline the importance of regulation of the GABAAR signalling for 




Polyglutamine expansion disorders are characterized by the formation of intranuclear 
as well as cytoplasmic inclusions or aggregates suggesting a direct correlation between 
neurodegeneration and aggregate formation. However, several studies have shown that 
the formation of inclusions is actually beneficial, supposedly through efficient storage 
of aggregation prone proteins (Arrasate et al., 2004; Saudou et al., 1998). A schematic 
representation of aggregation is given in Figure 4. Most likely, the detrimental effects 
of polyglutamine proteins are caused by their ability to aggregate and not by the 
full blown inclusions that function as protective storage mechanisms. Aggregation 
prone proteins are much more likely to interact with and disrupt cellular function of 
transcription factors, UPS components and chaperones in their soluble state.
Figure 3: Disturbed neurotransmitter trafficking and activity in HD.
Htt interaction partner Hap1 is responsible for transport of BDNF cargoes. (A) Binding of 
mutant Htt to kinesin and disturbed binding of Hap1 results in increased vesicle stalling and 
decreased neurotrophic support from the cortex towards the striatum. (B) Similarly, transport of 
GABAAR vesicle transport is disturbed resulting in decreased receptor density at the synapses. (C) 
Mutant Htt results in increased extrasynaptic NMDAR which results in glutamate excitotoxicity. 
Synaptic NMDA activation results in TCP-1 upregulation which promotes Htt inclusion 




Interestingly, in HD transgenic mice the behavioural phenotype as well as cellular 
dysfunction preceded the formation of NII or even microaggregates (Menalled et al., 
2002). This demonstrates in vivo that neuronal function is affected by the presence of 
expanded polyglutamine but visible aggregate formation is not required for disruption 
of cellular homeostasis. Additionally, lack of the self association region of ataxin-1 
resulted in similar neurodegeneration in SCA1 transgenics but these mice did not 
demonstrate any visible aggregates (Klement et al., 1998). Moreover, inducible HD 
mice demonstrated that acute expression of expanded polyglutamine proteins resulted 
in inhibition of the UPS (Ortega et al., 2010). This UPS impairment was rescued by 
the formation of inclusion bodies and aggregation inhibitors resulted in sustained 
impairment of the UPS. 
Figure 4: Misfolding of expanded Htt and formation of inclusion bodies.
Polyglutamine expansion in the Htt protein 
results in misfolding of the polyglutamine protein. 
Misfolded monomers tend to aggregate with other 
polyglutamine containing proteins resulting in 
oligomeric forms of the protein. The monomeric 
as well as oligomeric forms are most likely to 
interfere with normal cellular functions eventually 
resulting in toxicity. Further protein aggregation 
results in the formation of inclusion bodies which 
are actually protective as they decrease the levels 




The main protein degradation systems of the cell are the UPS and autophagy. 
Autophagosomes are responsible for the uptake of misfolded aggregated proteins and 
subsequent fusion with lysosomes for degradation of these proteins. Autophagy is 
involved in the degradation of mutant Htt in cellular models (Bjorkoy et al., 2005; Qin 
et al., 2003; Rideout et al., 2004).
Induction of autophagy was shown to be beneficial in animal models of several 
polyglutamine diseases and reduces neuropathology as well as phenotypic 
performance (Menzies et al., 2010; Pandey et al., 2007; Ravikumar et al., 2004). 
Clearance of aggregated proteins involves a direct interaction of the inclusions with 
p62/sequestosome-1 and requires microtubules and histone deacetylase 6 (HDAC6) 
(Bjorkoy et al., 2005; Iwata et al., 2005). Interestingly, p62 has been shown to bind 
directly to LC-3 as well as to ubiquitinated inclusions requiring its ubiquitin binding 
motif in order to facilitate autophagic degradation (Donaldson et al., 2003; Pankiv et 
al., 2007). Autophagic components as well as lysosomes require an intact microtubule 
cytoskeleton and HDAC6 could act directly through deacetylation of tubulin. 
Additionally, HDAC6 is required for deacetylation of Hsp90 and could therefore 
indirectly affect autophagy through activation of Hsp90 target proteins (Kovacs et 
al., 2005). Furthermore, specific acetylation of mutant but not wild type Htt results 
in increased association with autophagosomes through interaction with p62 (Jeong 
et al., 2009). This acetylation is likely to be regulated by the histone acetyltransferase 
domain of CBP and overexpression of CBP increases acetylation and consecutive 
degradation of mutant Htt.
Upon autophagy impairment, p62 accumulates and binds to poly-ubiquitinated 
targets resulting in inhibition of proteasomal degradation of these ubiquitinated 
targets (Korolchuk et al., 2009). The decreased proteasomal degradation can 
consecutively be rescued by down regulation of p62 suggesting that the impairment 
is indeed caused by direct binding of the substrates. Normally, p62 will shuttle these 
substrates to the autophagosome but prevents transport to the proteasome. Through 
nucleocytoplasmic shuttling p62 is also involved in transport of poly-ubiquitinated 
targets to promyelocytic leukemia bodies within the nucleus (Pankiv et al., 2010). 
Within the nucleus, both E3 ubiquitin ligases San1p and UHRF-2 – ubiquitin like 
with PHD and Ring finger domain-2 – can ubiquitinate Htt and thereby enhance 
intranuclear degradation of expanded polyglutamine proteins (Iwata et al., 2009). 
Altogether, this indicates that aberrant proteins can be targeted for degradation within 
the nucleus and protein quality control is not restricted to the cytoplasm alone. Lower 
levels of protein quality control proteins as well as the inability of autophagy to clear 
nuclear proteins can however contribute to preferential aggregation of polyglutamine 
proteins within the nuclear compartment. 
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Ubiquitin proteasome system 
Several links have been revealed between neurodegenerative diseases in general and the 
UPS (Ciechanover and Brundin, 2003). Genetic mutations in UPS components cause 
several forms of familial neurodegeneration and ubiquitin is found in the hallmarks 
of most neurodegenerative diseases including AD, PD and polyglutamine diseases. 
Furthermore, the UPS is involved in cellular protein quality control and responsible 
for the degradation of the aberrant proteins that accumulate in neurodegeneration. 
The UPS is a complex, tightly controlled system for the degradation of excessive or 
aberrant intracellular proteins. It contributes to cellular homeostasis by regulating 
the expression of essential proteins in a temporal and spatial pattern. The substrate 
to be degraded is tagged by multiple ubiquitin molecules followed by translocation to 
the proteasome where the protein is proteolytically processed. See also Figure 5 for a 
schematic representation of ubiquitination and the UPS.
Figure 5: The ubiquitin proteasome system.
Ubiquitin is activated by an E1 enzyme followed by transfer to an E2 ubiquitin conjugating enzyme 
and transfer to the E3 bound substrate. Currently two human E1s have been identified, over fifty 
E2s and hundreds of E3 enzymes indicative of increased substrate specificity of ubiquitin transfer. 
Consecutive ubiquitin moieties are attached to the ubiquitin on the substrate to form a poly-
ubiquitin chain, which functions in different cellular signaling pathways including proteasomal 
targeting. Ubiquitinated substrates are transported to the proteasome where they are unfolded 
and de-ubiquitinated by the 19S cap for insertion into the 20S proteolytic core for degradation 
into small peptides. These peptides are subsequently degraded by cytoplasmic proteases into amino 
acids and recycled.
Ubiquitination
The ubiquitin conjugation is accomplished by a cascade of proteins that activate (E1), 
conjugate (E2) and ligate (E3) ubiquitin to the target proteins (reviewed in (Pickart, 
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2001)). An E1 ubiquitin-activating enzyme binds ubiquitin at an internal cysteine 
residue via a high-energy thiol-ester bond in an ATP dependent reaction. Ubiquitin 
then transfers to one of several E2 ubiquitin-conjugating enzymes via another high-
energy thiol-ester bond. Finally, ubiquitin transfers to a lysine residue of the substrate 
that is specifically bound by an E3 ubiquitin-ligating enzyme. For most ubiquitin 
signalling, including proteasomal degradation, multiple ubiquitin proteins are linked 
to form a poly-ubiquitin chain on the target protein (Thrower et al., 2000).
There are many E3 enzymes that recognize specific target sequences and are subdivided 
into four distinct families on the basis of their binding domains (Kim and Huibregtse, 
2009; van Wijk et al., 2009). Firstly, the HECT-domain E3s – for homologous to E6-
AP C-terminus – generate an additional high-energy thiol-ester bond on an internal 
cysteine residue, before transfer of ubiquitin to the substrate. Secondly, the RING 
finger containing E3s – for really interesting new gene – catalyze the direct transfer of 
ubiquitin from E2 to the substrate by an active site of cysteines and histidine residues 
around two zink ions. Further families containing U-box and PHD – for plant 
homeo domain – probably catalyze the ubiquitin transfer in a similar way. Linking of 
additional ubiquitin proteins to form the polyubiquitin chain is regulated by the same 
cascade although in some cases a different ligase (E4) catalyzes chain elongation.
This cascade is involved in all ubiquitination reactions, irrespective of whether the 
bound ubiquitin will signal proteasomal targeting, protein expression or endocytosis. 
Importantly, the formation of different ubiquitin trees by linkage to another ubiquitin 
lysine residue on positions 6, 29, 48 or 63 confers part of the signalling specificity 
(Pickart and Fushman, 2004; Xu et al., 2009). Ubiquitin chains that are attached 
by K48 linkage are known to specifically target proteasomal degradation whereas 
K63 linkage is involved in trafficking and translation. The lysine residue within the 
substrate that is ubiquitinated possibly contributes to this specificity. Importantly, 
ubiquitination is involved in several cellular processes which indicates an important 
role for the ubiquitination machinery in the cells.
Proteasomal degradation
Recruitment to the proteasome by multi-ubiquitin chain binding proteins (MCBP) 
confers additional substrate specificity. Proteins such as Rad23, Dsk2 and Ddi1 
shuttle specific substrates to the proteasome by binding to the ubiquitin chains with a 
ubiquitin-associated (UBA) domain and to the proteasomes with a ubiquitin-like (UbL) 
domain (Elsasser et al., 2004; Kim et al., 2004; Verma et al., 2004). The proteasome 
subunit Rpn10 similarly contains the ability to bind multi-ubiquitin chains, although 
in yeast this subunit is dispensable suggesting involvement of other factors in binding 
ubiquitinated targets to the proteasome (van Nocker et al., 1996). In addition, the 
Rpt5 subunit has been shown to bind ubiquitin chains in intact proteasomes requiring 
ATP-hydrolysis (Lam et al., 2002).
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The proteasome itself consists of a multi-subunit complex that is normally subdivided 
in two regulatory 19S cap structures on both sides of the 20S proteolytic core. Upon 
binding of the ubiquitinated substrate to the 19S cap, the ubiquitin molecules are 
recycled and the substrate is unfolded, chaperoned and consecutively inserted into 
the 20S core. The core contains trypsin-like, chymotrypsin-like and peptidyl-glutamyl 
peptide hydrolizing (PGPH) activities which are responsible for specific cleavage of 
the substrate into small peptide fragments. 
Alternatively, association of the 20S core with one or two 11S structures can be 
induced by interferon-γ and the resulting immunoproteasome is involved in MHC 
class I antigen presentation. In addition, interferon-γ induces the LMP2, LMP7 
and MECL-1 subunits that replace the normal catalytic β-subunits in the 20S core. 
These modifications result in the exit of larger peptides from the proteasome that 
are eventually used for antigen presentation (Fruh et al., 1994). In HD, neuronal 
induction of the immunoproteasome was detected showing increased levels of LMP2 
and LMP7 (Diaz-Hernandez et al., 2003). Strikingly, this potentially accounts for the 
observed increase in both trypsin- and chymotrypsin-like activities without affecting 
the PGPH activity. This could either be induced by inflammatory cytokines like 
interferon-γ released by reactive glia or a direct response of the neuron to cope with 
the expanded polyglutamine repeats which are difficult to degrade. However, deletion 
of the proteasome activator REGγ, which suppresses the PGPH activity, failed to 
improve proteasomal activity or neuropathological symptoms in R6/2 mice (Bett et 
al., 2006). Thus, activation of the proteasomal PGPH activity is not sufficient to rescue 
cells from high levels of mutant huntingtin.
 
Coaggregation of proteins and chaperones
In polyglutamine diseases, the inclusions contain ubiquitin or ubiquitinated proteins 
which indicates that the aggregating proteins are targeted for degradation by the 
proteasome (DiFiglia et al., 1997; Paulson et al., 1997). In addition, inclusions in 
polyglutamine diseases have been shown to recruit at least parts of the 26S proteasome 
and expanded polyglutamines inhibit proteasomal activity in vitro (Bence et al., 2001; 
Schmidt et al., 2002). 
Several proteins coaggregate with NIIs in polyglutamine diseases but most notable 
are the chaperone proteins including heat-shock proteins and components of the UPS 
and autophagy pathway. These clearance mechanisms include proteins involved in 
refolding, degradation and autophagy. Alternatively, these proteins could function in 
the efficient assembly of aggresomes which function to clear the cell of detrimental 
aggregation prone proteins. Both p62 as well as non-expanded ataxin-3 are sequestered 
into aggregates requiring their ubiquitin binding motifs (Donaldson et al., 2003). 




The stress response or heat-shock proteins (Hsp) are involved in refolding of misfolded 
proteins or alternatively degradation by the proteasome. Polyglutamine aggregates 
of several disorders, including SBMA and SCA1, have been shown to contain Hsps 
(Cummings et al., 1998; Stenoien et al., 1999). Additionally, overexpression of Hsp40 
decreased aggregation of expanded polyglutamine proteins. In vitro both Hsp40 and 
Hsp70 reduce aggregation of expanded HD exon-1 through direct binding to the 
polyglutamine repeat and separating the monomeric form (Muchowski et al., 2000; 
Wacker et al., 2004). In vivo, decrease of Hsp70 in R6/2 mice resulted in increased 
neuropathology and decreased survival although an increase was only observed of 
inclusion bodies and not of fibrillar aggregates (Wacker et al., 2009). Overexpression 
of Hsp70 indeed ameliorated the neuropathology and phenotype of transgenic mice 
of both SBMA and SCA1 (Adachi et al., 2003; Cummings et al., 2001). Most likely, 
Hsps respond to the misfolded protein by promoting proteasomal degradation of 
the expanded polyglutamine repeat protein (Bailey et al., 2002). Conversely, Hsp70 
overexpression in R6/2 mice failed to improve the neurological phenotype despite the 
slight delay in aggregate formation (Hay et al., 2004). Interestingly, pharmacological 
induction of the heat shock response did improve solubility of polyglutamine proteins 
through sustained chaperone induction. 
Furthermore, C-terminus of Hsp70 interacting protein (CHIP; a U-box E3-ligase) 
was shown to interact with expanded polyglutamine protein (Jana et al., 2005). 
Importantly, overexpression of CHIP increased ubiquitination of expanded Htt and 
ataxin-3 providing a direct link between the heat shock response and proteasomal 
degradation of expanded polyglutamine proteins. As a result, both aggregation as well 
as toxicity of expanded polyglutamine proteins was decreased in vitro and in vivo 
(Miller et al., 2005). Interestingly, overexpression of CREB and Hsp70 in Drosophila 
additively suppresses polyglutamine toxicity (Iijima-Ando et al., 2005). These results 
clearly demonstrate differential defects leading to toxicity in polyglutamine diseases 
as well as a lack of compensatory mechanisms. 
Proteasome inhibition
In polyglutamine diseases there are several indications of UPS impairment and 
a contribution of the UPS to neuropathology. In vitro, expanded polyglutamine 
proteins cause a relocation of the 20S proteasome core from the cytoplasm to the 
insoluble inclusions (Jana et al., 2001). This change results in a decrease in proteasome 
activity and consecutively diminishes degradation of normal cellular proteins like 
p53 resulting in increased cell death. Furthermore, expanded polyglutamines can 
directly inhibit the proteasome through direct binding (Bence et al., 2001; Verhoef et 
al., 2002). In addition, the ability of aggregate forming cells to respond to secondary 
stress-insults like heat shock is decreased (Ding et al., 2002). 
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In SCA3 and HD patients, besides ubiquitin also subunits of the 26S proteasome have 
been shown to be recruited to NIIs (Figure 6) (Chai et al., 1999; Schmidt et al., 2002). 
In SCA1 transgenic mice, the Purkinje cell pathology was aggravated by mutation of 
the E6-AP ubiquitin ligase (Cummings et al., 1999). Altogether, these findings point 
towards an involvement of the UPS in the pathogenesis of polyglutamine diseases 
and to an enhancement of neurodegeneration by further impairment of the UPS 
(Ciechanover and Brundin, 2003).
Proteasome inhibition in R6/2 mice demonstrates controversial results. Both the 
ubiquitin proteasome reporters GFPu as well as UbGFP failed to show an accumulation 
of these reporters in R6/2 mice despite accumulation of ubiquitin conjugates, 
suggested to be caused by compensatory mechanisms (Bett et al., 2009; Maynard et al., 
2009; Ortega et al., 2010). Interestingly, in these and other studies a buildup of large 
ubiquitin conjugates was detected pointing towards a disruption in the degradation 
machinery in these mice (Bennett et al., 2007). Possibly, large polyglutamine 
fragments are incapable of entering the proteasome in vivo and consequently do not 
result in clear inhibition of the 26S activity. Inducible mouse models have shown 
that UPS impairment is seen upon acute expression of polyglutamine whereas this 
was not detected upon chronic expression of expanded polyglutamine (Ortega et al., 
2010). In Htt knock-in mice with endogenous expression levels of expanded Htt no 
Figure 6: Colocalization of proteasome subunits with NIIs.
Immunohistochemical staining shows that several proteasome subunits are translocated into the 
NIIs in HD. (A-B) Apparent upregulation of 20S subunits β1 (A) and β1i (B) in the frontal cortex 
of HD but colocalization is only observed for the β1i subunit. (C) Similar upregulation is found 
for 11S subunit REGβ as well as colocalization with NII. Several 19S subunits colocalize with NII 
including Rpt2 / S4 (D), Rpt3 / S6B (E) and Rpn2 / S1 (F). 
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inhibition of the UPS or autophagy activation was detected (Li et al., 2010). However, 
pharmacological inhibition of the UPS did result in a larger buildup of N-terminal 
mutant Htt compared to inhibition of autophagy, demonstrating a more important 
function for the UPS in the clearance of Htt.
In vitro it has been shown that expanded polyglutamine proteins result in direct 
inhibition of the proteasome and the repeats themselves are difficult to degrade (Bence 
et al., 2001; Holmberg et al., 2004). It would be interesting to test a mouse model with 
later onset HD in order to discern whether the prolonged expression of mutant Htt 
does result in decreased proteasome activity. Furthermore, the early expression of 
exon 1 of HTT with an extreme repeat expansion could account for compensatory 
mechanisms to deal with the mutant protein. Although expanded polyglutamine 
proteins have been shown to inhibit the proteasome, further expansion will result 
in more aggregation prone proteins with potentially decreased ability to enter and 
thereby block the proteasome. Most likely, certain aggregation intermediates do have a 
detrimental effect other than the proteasome causing neuropathology in these mice. 
Aberrant ubiquitin - UBB+1
Ubiquitin is a highly expressed protein that is essential for cellular function. Mutations 
in other components of the UPS result in several forms of familial neurodegeneration. 
In AD, an aberrant form of ubiquitin (UBB+1) accumulates in the neuropathological 
hallmarks of the disease (van Leeuwen et al., 1998). This UBB+1 protein is formed 
by a dinucleotide deletion (ΔGU), leading to a +1 reading frame in the mRNA, and 
subsequent translation to a protein with an aberrant C-terminus. Thus far UBB+1 
protein has been found in the hallmarks of several neurodegenerative diseases, 
including AD and other tauopathies, whereas it was not detected in synucleinopathies 
and young control patients without pathology (Fischer et al., 2003; van Leeuwen et 
al., 1998). The aberrant transcript however, in contrast to the protein, appeared to be 
present even in young controls. Under normal circumstances, neurons can apparently 
cope with UBB+1, and accumulation of this protein reflects proteasomal dysfunction 
in different neuropathological disorders (Fischer et al., 2003).
In vitro studies have shown that, although UBB+1 can be ubiquitinated and degraded 
by the proteasome, at higher concentrations it also inhibits proteasomal degradation 
of cellular proteins and leads to cell death in neuroblastoma cells (Lindsten et al., 
2002; van Tijn et al., 2007). UBB+1 can no longer ubiquitinate substrate proteins, and 
was shown to be a reporter for proteasomal dysfunction (Fischer et al., 2003). In 
addition, UBB+1 has been implicated to mediate neurodegeneration via downstream 
interaction with the E2-25K ubiquitin conjugating enzyme, which induces amyloid-β 
neurotoxicity in vitro (Ko et al., 2010; Song et al., 2003). Furthermore, E2-25K is highly 
expressed in the brain and was found in a yeast two-hybrid screen to interact with Htt 
in a repeat-independent matter (Kalchman et al., 1996). In this perspective, UBB+1 
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might accelerate disease progression and increase the severity of neurodegeneration. 
Notably, the proteasome activity is indeed decreased in AD (Keck et al., 2003; Keller 
et al., 2000), strengthening the idea that UBB+1 accumulation is intimately related 
to impairment of the proteasome (Ciechanover and Brundin, 2003; Tank and True, 
2009). Interestingly, neurotoxicity of mutant Htt has also been shown to increase upon 
ageing suggesting a decreasing cellular capacity to handle aberrant proteins (Diguet 
et al., 2009). Altogether, different proteins start to accumulate at later stages in life 
indicating similar mechanisms that lead to the build up and consecutive neurotoxic 
properties.
Concluding remarks and aim of this thesis
The UPS is essential for normal cellular function by degrading proteins that are no longer 
required, become damaged or are aberrant. Degrading surplus proteins is especially 
important for non-dividing cells like neurons that lack the capability to replace ageing 
cells (Keller et al., 2002). Strikingly, decreased activity of the UPS has been shown 
upon ageing and aberrant proteins like UBB+1 are only detected in aged individuals 
(van Leeuwen et al., 1998). Despite expression from development, neurodegenerative 
disorders including the polyglutamine diseases manifest themselves around mid-life 
suggesting a buildup of aberrant proteins or cellular injury (Ciechanover and Brundin, 
2003). It appears likely that factors like the UPS that become affected upon ageing 
influence development of these disorders.
The aim of this thesis was to elucidate the contribution of the UPS to neurodegeneration 
in HD. Several aspects of neurodegeneration in HD with a specific focus on the UPS 
are reviewed in Chapter 1.
Chapter 2 reviews the discovery of molecular misreading which occurs on GAGAG 
motifs in different genes. The frameshift mutant of ubiquitin B (UBB+1) is described 
including the contribution to disease development.
UBB+1 was shown to accumulate in AD and is an in vivo marker for proteasomal 
inhibition in neurodegenerative disorders. As described in Chapter 3, we wanted to 
elucidate whether the proteasome is also impaired in HD and SCA3 in vivo which 
would lead to the accumulation of UBB+1. In addition, we investigated whether UBB+1 
could affect neurodegeneration in an in vitro model for HD.
UBB+1 transgenic mice show a mild inhibition of the proteasome. The aim of Chapter 
4 was to examine whether this UPS inhibition by UBB+1 influences Htt aggregation in 
vivo. In general, we wanted to clarify whether a modest inhibition of the proteasome 
could have a significant impact on the neuropathology of HD.
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The ubiquitin conjugating enzyme E2-25K has been shown to interact directly 
with Htt independent of polyglutamine repeat length. In Chapter 5, we questioned 
whether the sub-cellular localization of E2-25K was altered in disease as a result of the 
polyglutamine expansion. Additionally, we examined whether the interaction of Htt 
with E2-25K is involved in neurodegeneration in HD. 
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Abstract
It is increasingly appreciated that failures in the ubiquitin-proteasome system play a 
pivotal role in the neuropathogenesis of many neurological disorders. This system, 
involved in protein quality control, should degrade misfolded proteins, but apparently 
during neuropathogenesis, it is unable to cope with a number of proteins that, by 
themselves, can consequently accumulate. Ubiquitin is essential for ATP- dependent 
protein degradation by the proteasome. Ubiquitin+1 (UBB+1) is generated by a 
dinucleotide deletion (ΔGU) in UBB mRNA. The aberrant protein has a 19 amino 
acid extension and has lost the ability to ubiquitinate. Instead of targeting proteins for 
degradation, it has acquired a dual substrate-inhibitor function; ubiquitinated UBB+1 
is a substrate for proteasomal degradation, but can at higher concentrations inhibit, 
proteasomal degradation. Furthermore, UBB+1 protein accumulates in neurons and 
glial cells in a disease-specific way, and this event is an indication for proteasomal 
dysfunction. Many neurological and non-neurological conformational diseases have 
the accumulation of misfolded proteins and of UBB+1 in common, and this combined 
accumulation results in the promotion of insoluble protein deposits and neuronal cell 
death as shown in a cellular model of Huntington disease.
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Introduction
Only at the 9th Alzheimer meeting in Philadelphia, 2004, “conformational diseases” 
were acknowledged as a group of disorders that share a common feature: the 
accumulation of insoluble protein deposits in the affected cells (Carrell and Lomas, 
1997). To this group belong many age-related neurodegenerative disorders, such 
as tauopathies (e.g. Alzheimer and Pick disease), synucleinopathies (e.g. Lewy 
body disease) and polyglutamine diseases (e.g. Huntington disease, and several 
spinocerebellar ataxias) (Ciechanover and Brundin, 2003; Landles and Bates, 2004). 
In addition, in non-neuronal disorders inclusions are present as well (e.g. alcoholic 
liver disease, inclusion body myositis and α1-antitrypsin deficiency (Askanas and 
Engel, 2003; French et al., 2001; Lomas and Carrell, 2002; McPhaul et al., 2002). 
Although the deposits vary in protein composition, shape and localization, each of 
these structures (e.g. aggregates, aggresomes or inclusions) is mainly composed of 
insoluble misfolded proteins (e.g. Huntingtin, α-synuclein or hyperphosphorylated 
tau), different molecular chaperones (e.g. heat shock proteins) and various 
components of the ubiquitin-proteasome (UPS) (e.g. E3 ligases such as CHIP, 19S 
and 20S proteasomal subunits of the 26S proteasome) (McDonough and Patterson, 
2003; Sherman and Goldberg, 2001). The presence of these factors suggests that these 
insoluble proteins are misfolded and have been targeted for degradation, but instead 
of being properly refolded or proteolytically degraded, they accumulate in insoluble 
protein deposits (Alves-Rodrigues et al., 1998). The coexistence of heat shock proteins 
and UPS compounds is expected, since one of the fundamental tasks of the UPS is to 
degrade damaged or abnormal proteins and to protect cells during stress responses. If 
the capacity of the UPS is exceeded (e.g. during aging (Keller et al., 2004)), autophagy, 
essential for the elimination of aggregates, is induced. Autophagy is considered a 
highly regulated but non-selective pathway by which cytoplasmic constituents are 
degraded in lysosomes (see (Cuervo, 2004; Nixon, 2005; Ross and Pickart, 2004)). In 
the past few years excellent reviews on cross-talk between the UPS (Keller et al., 2004; 
Pickart and Cohen, 2004) and autophagy (Shintani and Klionsky, 2004) in relation 
to neurodegeneration have appeared (Ciechanover and Brundin, 2003; de Vrij et al., 
2004; McNaught, 2004; Ross and Poirier, 2004).
In the present minireview the discovery of an unexpected type of mutation (“molecular 
misreading”) and the contribution of one of the resulting aberrant proteins (UBB+1) 
to proteasomal dysfunctioning will be discussed in relation to various conformational 
diseases that have an impaired UPS (Song and Jung, 2004).
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Figure 1: Molecular misreading.
Schematic representation of the vasopressin (VP) gene, its precursor protein and its mutant forms. 
The VP gene was cloned in the early eighties and consists of 429 nucleotides divided over three 
exons. After splicing, a precursor protein is translated at the endoplasmatic reticulum which is 
enzymatically processed within granules and subsequently transported to the nerve terminals. In 
the normal situation (A) a wild-type (wt) VP precursor is synthetized in the supraoptic nucleus 
(SON) that can be posttranslationally processed and packaged in neurosecretory granules that are 
subsequently axonally transported towards the neural lobe. The homozygous Brattleboro rat (B) 
lacks a single G base in exon B by which an out of frame mutant protein is formed with a polylysine 
tail that cannot be processed properly. As a result a severe diabetes insipidus (DI) develops. The 
volume of urine formed daily can reach 70% of the body weight. This trait is autosomally recessive 
and inherited in a simple Mendelian manner. In the SON and the paraventricular nucleus 
surprisingly an age-dependent increase of solitary neurons with a revertant VP phenotype (C, 
diagram) was found (van Leeuwen et al., 1989) that appeared to be due to a second mutation 
(ΔGA) in downstream located GAGAG motifs. As a result the VP (mutant) precursor (i.e. the 
glycoprotein-containing part) can be processed and the neurosecretory granules can be axonally 
transported again towards the neural lobe (Evans et al., 1996). As GAGAG motifs are also present 
in the wt-VP gene of rat and human (D), a similar process can take place and change the normal 
VP precursor in an aberrant one. This was shown in neurons of the SON of the rat (D1) and the 
human (D2). 
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Discovery of molecular misreading
Molecular misreading of genes (i.e. the inaccurate conversion of genomic information 
into aberrant proteins) was demonstrated in the vasopressin (VP) gene, which is 
highly expressed in magnocellular neurons of the hypothalamo-neurohypophyseal 
system. The first occurring knockout ever presented was that of VP, discovered in the 
city of Brattleboro (Vermont, USA (Valtin, 1982); Figure 1). Gene cloning revealed 
the mutation; a single G residue deletion in exon B results in a VP precursor with 
a very sticky polylysine C-terminus which remains in the endoplasmatic reticulum. 
Antibodies raised against all parts of the VP precursor (e.g. the very C-terminal part 
of the VP precursor; glycopeptide) showed an intense staining of VP cells (Figure 
1A). As a specificity control for these antibodies, the homozygous Brattleboro rat 
was used. Indeed, many neurons in the magnocellular hypothalamic nuclei showed 
no reaction (Lu et al., 1982). However, surprisingly, solitary neurons were intensely 
stained with glycopeptide antibodies (Figure 1B,C). These neurons, which had a 
revertant VP phenotype, were shown to increase in number with advancing age by 
the diseased state (diabetes insipidus) of these animals (Evans et al., 1994). Follow-up 
analysis of the mRNA of these cells revealed dinucleotide deletions (ΔGA) located 
downstream of the G deletion, in GAGAG motifs. Consequently, at these points the 
normal reading frame was restored.
Subsequently, the question was raised whether this mutation is a peculiarity of 
the Brattleboro rat or a more general phenomenon. The wild-type VP genes of rat 
and human have the same GAGAG motifs. Indeed, antibodies directed against the 
predicted VP sequences in the -2 or +1 reading frame resulted in an intense staining 
of magnocellular neurons (Figure 1, D1 and D2; (Evans et al., 1996)). Thus, a similar 
dinucleotide deletion (ΔGA) is likely to occur in wild-type sequences and is not 
restricted to homozygous Brattleboro rats. It is important to realize that in these cases 
an abnormal precursor protein is created out of a normal one. These abnormal +1 
proteins are potentially functionally different (Figure 1D).
Which transcripts have GAGAG motifs?
The next step was to see if other genes do have GAGAG motifs or other simple repeats. 
The chance to encounter a GAGAG motif is 1:1024, and there are many genomic 
sequences which have such a potential, error-prone site. We focused on Alzheimer’s 
disease associated genes such as β amyloid precursor protein and ubiquitin B, of 
which indeed the respective +1 proteins were found to coexist in the hallmarks of 
all cases of Alzheimer’s disease (including sporadic ones) and Down syndrome (van 
Leeuwen et al., 1998). The proposed dinucleotide deletions were found as well. The 
existence of these dinucleotide deletions was confirmed independently (van den Hurk 
et al., 2001). Several +1 proteins appeared to coexist (e.g. Amyloid Precursor Protein, 
Ubiquitin and GFAP; Figure 2) due to molecular misreading and exon skipping (Hol 
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Figure 2: Various +1 stainings in comparison to their wild-type form or conventional 
markers.
Fifty-μm-thick vibratome section of the 
hippocampus of an Alzheimer patient 
(AD, #96115, 90 years old) showing Aβ, 
APP+1, ubiquitin, UBB+1, GFAP and 
GFAP+1. Abnormal Tau is present in 
the hallmarks of AD (G, neurofibrillary 
tangles, neuropil threads and 
dystrophic neurites) similar to APP+1, 
Ubiquitin, UBB+1 and remarkably 
with GFAP and GFAP+1 (Hol et al., 
2003). Note in panel E that GFAP also 
reacts with astrocytes. In panel H the 
19S regulator subunit 6b is present 
in the same hallmarks indicating its 
upregulation (patient #88028, paraffin 
section, (Zouambia et al., 2008)) and 
proteasomal dysfunction that can be 
explained by the presence of UBB+1 by 
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et al., 2003). We subsequently focused upon ubiquitin B because of the potentially 
devastating effects of both a gain or loss of function of the resulting +1 protein in 
different cellular processes (Ciechanover and Brundin, 2003).
Ubiquitin B and molecular misreading
Human ubiquitin B is a protein localized on chromosome 17p11.2 and it is one of the 
best conserved eukaryotic proteins. From yeast to human, only at three positions does 
the amino acid sequence show variation in the 76 residues long protein, indicating 
its functional relevance. Ubiquitin B is synthetized in a three repeat from which 
76 amino acids are cleaved off. The ubiquitin molecule harbors a number of lysine 
moieties, of which #29 and #48 are involved in ATP-dependent multi-ubiquitination, 
a process that triggers transport to the proteasome, followed by proteolysis. At the 
very C-terminus of ubiquitin a glycine moiety (#76) is present, which is essential for 
all biological function of ubiquitin B. A few nucleotides upstream of this C-terminal 
glycine moiety a GAGAG motif is present. The result of a dinucleotide deletion in this 
motif is a loss of the C-terminal glycine moiety and a 19 amino acids longer ubiquitin 
molecule called ubiquitin+1 (UBB+1) (Figure 3). It was suggested that UBB+1 is unable 
to ubiquitinate and in fact, might be a substrate for ubiquitination (van Leeuwen et 
al., 1998), and disturb proteasomal degradation as mentioned in Vogel (Vogel, 1998).
Towards an effect of ubiquitin+1
The functional relevance of UBB+1 has been clarified during the past five years. 
UBB+1 can be degraded at low concentrations (Lindsten et al., 2002), apparently 
after deubiquitination, but is also refractory to deubiquitination (Lam et al., 2000). 
Ubiquitinated UBB+1 furthermore appears to inhibit the proteasome potently (Lindsten 
et al., 2002). In case of high concentrations, neuronal cell death by apoptosis was found 
(De Vrij et al., 2001). Since deubiquitination of UBB+1 is a prerequisite for its entrance, 
subsequent unfolding, substrate recognition, chaperoning and channelling by 19S 
regulatory subunits to the 20S proteolytic core are possibly disturbed. Consequently, 
degradation of UBB+1 by the β 1, 2 and 5 subunits in the proteolytic core is impaired 
(Pickart and Cohen, 2004).
The next step to find out whether UBB+1 contributes to the neuropathogenesis of 
Alzheimer’s disease, was to generate transgenic mice expressing UBB+1 regionally 
(hippocampus and cerebral cortex). This work has been executed successfully is 
in progress; we are currently using these transgenic UBB+1 mice to explore the 
downstream effects of UBB+1 (e.g. proteomic and behavioral analyses, long-term 
potentiation (LTP) and transcript and protein analysis of gene products involved 
in LTP, e.g. CREB; (Hegde, 2004)). Indeed, UBB+1 induces expression of heat shock 
proteins, as shown in human neuroblastoma cells (Hope et al., 2003), and a behavioral 
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Figure 3: Multiubiquitination of proteasome substrates. 
Simplified and schematic representation of how ubiquitin acts via multiubiquitination through a 
number of enzymatic steps (E1, E2 and E3) (left panel, for details see (Ciechanover and Brundin, 
2003)). The lysine moieties at positions 29 and 48 are involved in the multiubiquitination and 
degradation. At the C-terminus of ubiquitin a GAGAG motif is present. It was shown that adjacent 
to this motif a dinucleotide deletion (ΔGU) occurs resulting in an extension of 19 amino acids 
(right panel, for further details see (Gerez et al., 2005)). Due to the dinucleotide deletion, the G76 
moiety at the C-terminus, essential for binding to a target protein, is not synthetized. Consequently 
this molecule cannot ubiquitinate. In fact, it has become a substrate for degradation and contains 
a ubiquitin fusion degradation signal as well. It has been shown that ubiquitinated UBB+1 protein 
inhibits the proteasome (Lindsten et al., 2002) and acts synergistically with polyglutamine repeats 
with regard to aggregation and cell death in a cellular model of HD (de Pril et al., 2004). 
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phenotype was found accompanied by other proteomic changes in these mice (Fischer 
et al., 2009). In this manner UBB+1 mouse lines have become available with a life-long 
genetically encoded inhibition of the proteasome. These unique lines can be used 
for crossing with other Alzheimer transgenic lines and other mouse models that are 
currently being used for other types of tauopathies (e.g. frontotemporal dementia) and 
Huntington disease. UBB+1 is present in the hallmarks of other tauopathies (Fischer et 
al., 2003) and polyglutamine diseases (Figure 4A-C) (de Pril et al., 2004). It was shown 
in a cellular model for Huntington disease (HD) that UBB+1 has a strong synergistic 
effect on aggregate formation and cell death (Figure 4D) (de Pril et al., 2004). These 
results are in agreement with the conclusion of Wexler et al. (Wexler et al., 2004), who 
reported that approximately 40% of the variance remaining in onset age is attributable 
to genes other than the HD gene and 60% is environmental. 
Fischer et al. (Fischer et al., 2003) showed in the rat brain that UBB+1 requires the 
lysine moieties of position 29 and 48 for its proteasomal degradation. It appeared that 
under normal circumstances in both the rat brain and in young non-demented control 
patients UBB+1 can be degraded rapidly and only accumulates upon proteasomal 
impairment. In other words, the accumulation of UBB+1 in various tauopathies and 
polyglutamine diseases, but not in synucleinopathies, points to UBB+1 as a marker for 
proteasomal dysfunction (de Pril et al., 2004; Fischer et al., 2003). The latter results 
indicate a difference between tauopathies and polyglutamine diseases at one side and 
synucleinopathies at the other one. In synucleinopathies the ubiquitin machinery may 
be disturbed, as shown in rare forms of Parkinson’s disease; the E3 ligase Parkin, the 
deubiquitinating enzyme ubiquitin carboxy terminal hydrolase UCH-L1, α-synuclein 
and DJ1 are mutated in familial forms of Parkinson’s disease (Ciechanover and 
Brundin, 2003; Giasson and Lee, 2003). In tauopathies and several polyglutamine 
diseases, accumulation of UBB+1 (possibly following a failure to deubiquitinate; 
(Lam et al., 2000)) and other substrates of the proteasome (e.g. Aβ, huntingtin) 
inhibit the proteasome (Lindsten et al., 2002). However, whether or not the ubiquitin 
machinery or the proteasome itself is impaired, both in tauo- and synucleinopathies, 
and in polyglutamine diseases, proteasomal dysfunction is the outcome in all these 
neurological disorders.
Molecular misreading in non-neuronal cells
Again using the VP system, we were able to address the question whether molecular 
misreading occurs outside of neuronal cells. In order to do so we used transgenic mice 
in which the rat VP gene is expressed ectopically in epithelial structures of secretory 
organs under the control of the mouse mammary tumor virus long terminal repeat 
promotor. Indeed, VP was found in the gonadal system (e.g. testis and epididymis). 
Using antisera specific for frameshifted VP (VP+1), we were able to show that in 
the principal cells of the caput of the epididymis VP+1, VP and other parts of the 




Figure 4: UBB+1 accumulates in polyglutamine diseases and enhances aggregate formation 
and cell death. 
UBB+1 was found to accumulate in all thirty cases of Huntington disease tested (A, striatum, #4 
of (de Pril et al., 2004), having 59 glutamine repeats, insert shows various intranuclear inclusions 
(blow-up of A, 1.3x) and B, frontal cortex of #5 in (de Pril et al., 2004), having 41 glutamine 
repeats). The same reaction was found in six cases of spinocerebellar ataxia-3 (C, pons of #36 in 
(de Pril et al., 2004), having a polyglutamine repeat length 24-70). Note the intense staining in 
the intranuclear inclusions as well as the cytoplasmic accumulation of UBB+1. Digital recordings 
of 6-μm-thick paraffin sections were made by the extended-depth program by which different 
pictures were combined to give one in-focus composite image (Imagepro 5.0, Media Cybernetics, 
Silver Springs, USA). Bar = 20 μm. D, In a cellular model of HD we found that UBB+1 not only 
increases the aggregate formation of expanded polyglutamine repeats but in addition has a 
synergistic effect on polyglutamine-induced cell death. Differentiated SH-SY5Y neuroblastoma 
cells were lentivirally infected with constructs with truncated huntingtin fragments containing 19 
or 43 glutamine repeats (HA-Q-GFP) in combination with either UBB+1;K29,48R or UBB+1. Cells were 
quantified for aggregate formation 4 days after infection (left panel). Note that huntingtin with 19 
glutamines does not result in the formation of aggregates. Constructs with 43 glutamines show a 
marked increase in the number of aggregate forming cells in the presence of UBB+1. Cell-death was 
assessed by a cell survival assay 4 days after infection (right panel). Polyglutamine-GFP positive 
cells were analyzed by flow cytometry for the percentage of cell death under different conditions 
(de Pril et al., 2004). Q19 with UBB+1;K29,48R shows the background percentage of cell death due 
to infection or culturing. A minor increase in cell death was observed with either expansion of 
the polyglutamine repeat or co-infection of UBB+1 with Q19. A marked increase in cell death was 
observed after coinfection of UBB+1 with the construct with 43 glutamines (n=3; P<0.005; for 
details see (de Pril et al., 2004)).
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(Van Leeuwen et al., 2000). Thus, VP+1 is formed in non-neuronal cells (molecular 
misreading), due to molecular misreading of the transgene. Subsequently, frameshifted 
ubiquitin (UBB+1) was found in inclusions of various human diseases and suggests 
a similar mechanism as found in neuronal cells: the Mallory bodies of hepatocytes 
during cirrhosis in alcoholic liver disease (McPhaul et al., 2002), in hepatocytes of 
patients with an α1-antitrypsin deficiency (Wu et al., 2002) and in aggregates of 
inclusion body myositis (Fratta et al., 2004).
The unfolded protein response and the UPS 
Many newly synthetized proteins are translocated into the lumen of the endoplasmic 
reticulum (ER), which is the place for their folding and assembly. Alterations in 
homeostasis by various cellular stressors that prevent protein folding cause an 
accumulation of misfolded proteins in the ER, which are referred to as types of ER 
stress. Eukaryotic cells can adapt, for survival, to deal with an accumulation of unfolded 
proteins in the ER by various signals from the ER lumen to the cytoplasm and the 
nucleus. This induction system is called unfolded protein response (UPR) and includes 
the transcriptional induction of UPR target genes (e.g. ER-resident chaperones, such 
as GRP78/BiP to facilitate protein folding), translational attenuation of global protein 
synthesis and ER-associated degradation (ERAD). In conformational diseases such 
as Alzheimer’s disease, recent reports indicate that the UPR is involved (Katayama 
et al., 2004), and a link between ERAD and the UPS has been suggested (Kopito and 
Sitia, 2000; Kostova and Wolf, 2003). In addition, a proteasome independent ERAD 
pathway may exist (Donoso et al., 2005). So far no link between UBB+1 effects and the 
UPR activity has been reported.
Challenges for the next decade
It is evident that the UPS contributes substantially to conformational diseases, such •	
as Alzheimer’s disease, during which “it stops delivery” (Miller and Wilson, 2003). 
This might reflect a primary or secondary event. Of course one should realize that 
Alzheimer’s disease and other related inclusion diseases are multifactorial. The latter 
aspect needs to be kept in mind when generating transgenic mice. The step towards 
multiple transgenic mice has been taken (e.g. (Oddo et al., 2004)) and the numerous 
contributing factors to Alzheimer’s disease can be organized in a temporal pattern 
(e.g. (Konishi et al., 2003; Muchowski and Wacker, 2005; Song and Jung, 2004)). 
The recently generated UBB+1 mouse lines are an obvious candidate for further 
crossings. Long term potential (LTP) measurements in the hippocampus of these 
mice and changes in gene and protein levels (e.g. CREB, synaptophysin and AMPA 
receptors, (Hegde, 2004)) as well as further proteomic analysis (Fischer et al., 2009) 
are currently under investigation. 
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Synaptic plasticity is also known to be affected in Alzheimer’s disease (Terry and •	
Katzman, 2001). The UPS and its inhibition by UBB+1 are attractive candidates for 
further research (Ehlers, 2003). The recently developed transgenic UBB+1 mice 
(Fischer et al., 2009) may contribute in this respect.
Another challenge is trying to substantiate the effects of different cellular stressors •	
(e.g. Aβ, E2-25K/Hip2, UBB+1) by introducing them into cell lines followed by rescue 
experiments, i.e. silencing the effect of these proteins by means of RNA interference 
(Novina and Sharp, 2004), as shown by Song et al. (Song and Jung, 2004).
The presence of UBB•	 +1 outside the nervous system, in dividing cells, enabled 
experiments in vitro to assess the contribution of UBB+1 to aggresome formation 
(e.g. (Bardag-Gorce et al., 2003; French et al., 2001)). Indeed, when the capacity of 
the proteasome is exceeded, aggregate formation followed by lysosomal degradation 
has become an increasingly attractive subject of research (e.g. (Shintani and 
Klionsky, 2004)). Other possible mechanisms to cope with insoluble proteins are 
posttranslational modifications like sumoylation and neddylation (e.g. (Schwartz 
and Hochstrasser, 2003; Steffan et al., 2004)), the contribution of which to inclusion 
formation in the various conformational diseases needs to be assessed.
Relevant essential subunits of the ubiquitin and deubiquination machinery as •	
well as of essential proteasome subunits are now ready for analysis to reveal their 
contribution to neuropathogenesis (e.g. (Cookson, 2004; Guterman and Glickman, 
2004; McDonough and Patterson, 2003; Petrucelli et al., 2004)).
It is clear that proteasomal activators are badly needed (without side-effects). •	
Proteins as activators of the 20S proteolytic core are known as PA28 and PA200, and 
are obvious targets for the development of even more potent molecules mobilizing 
the proteolytic machinery (Rechsteiner and Hill, 2005). Alternatively elucidation 
of deubiquitinating enzymes (DUBS) by screening RNAi libraries might result in 
DUBS promoting deubiquitination of ubiquitinated UBB+1 (Brummelkamp et al., 
2003).
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Abstract
Polyglutamine diseases are characterized by neuronal intranuclear inclusions of 
expanded polyglutamine proteins, indicating failing protein degradation. UBB+1, 
an aberrant form of ubiquitin, is a substrate and inhibitor of the proteasome, and 
was previously reported to accumulate in Alzheimer disease and other tauopathies. 
Here we show accumulation of UBB+1 in the neuronal intranuclear inclusions and 
the cytoplasm of neurons in Huntington disease and spinocerebellar ataxia type 3, 
indicating inhibition of the proteasome by polyglutamine proteins in human brain. We 
found that UBB+1 not only increased aggregate formation of expanded polyglutamines 
in neuronally differentiated cell lines, but also had a synergistic effect on apoptotic cell 
death due to expanded polyglutamine proteins. These findings implicate UBB+1 as an 
aggravating factor in polyglutamine-induced neurodegeneration, and clearly identify 
an important role for the ubiquitin-proteasome system in polyglutamine diseases. 
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Introduction
At least nine different neurodegenerative diseases are known that are caused by the 
expansion of a CAG repeat in the coding region of a transcribed gene, including 
the spinocerebellar ataxias (SCAs) and Huntington disease (HD) (Nakamura et al., 
2001; Zoghbi and Orr, 2000). All these CAG expansion diseases are characterized by 
progressive neuronal dysfunction starting around adult-life and resulting in severe 
neurodegeneration. In the channelopathy SCA6, neurodegeneration is caused by a 
small CAG expansion (to 19-30 repeats) in a calcium channel subunit that presumably 
causes a change of function (Zhuchenko et al., 1997). The other eight diseases 
are probably caused by a gain of function of the proteins carrying the expanded 
polyglutamine repeat. The pathological repeat length for these genuine polyglutamine 
expansion disorders starts around 40 glutamine repeats in the affected gene, with 
increasing severity and earlier manifestation upon greater expansion (Zoghbi and 
Orr, 2000). 
One of the hallmarks of the pathology of polyglutamine diseases is the formation of 
neuronal intranuclear inclusions (NIIs) in the affected areas of the brain (DiFiglia 
et al., 1997). Although many of the proteins carrying the polyglutamine repeat have 
a cytoplasmic function, upon polyglutamine expansion they all form intranuclear 
inclusions that contain at least the expanded polyglutamine fragment. In HD, for 
instance, the NIIs contain only the N-terminal part of huntingtin with the polyglutamine 
stretch (DiFiglia et al., 1997; Maat-Schieman et al., 1999; Sieradzan et al., 1999; Zhou 
et al., 2003). The major pathological difference between the polyglutamine diseases 
is the regional distribution of neurodegeneration. In HD the striatum is the most 
severely affected area and the cortex is affected to a lesser extent (Halliday et al., 
1998). In SCA3, in contrast, neuronal degeneration occurs primarily in the nuclei 
of the brainstem and the spinal cord (Takiyama et al., 1994). This regional specificity 
is probably caused by differences in expression levels of the respective disease genes 
among the various brain regions or different vulnerability of various types of neurons. 
In addition to the repeat expansion, other factors, such as proteasomal activity and 
expression or recruitment of cellular chaperones, probably influence polyglutamine 
toxicity and disease development (Chan et al., 2002; Wexler et al., 2004; Willingham 
et al., 2003).
NIIs contain ubiquitin or ubiquitinated proteins, which indicates that the aggregating 
proteins are targeted to, but not degraded by, the proteasome (DiFiglia et al., 1997; 
Paulson et al., 1997). In vitro studies have furthermore shown that expanded 
polyglutamines can directly inhibit the proteasome (Bence et al., 2001; Verhoef et 
al., 2002). In addition, in SCA3 patients, subunits of the 26S proteasome have been 
shown to be recruited to NIIs (Chai et al., 1999; Schmidt et al., 2002). Finally, in 
SCA1 transgenic mice, the Purkinje cell pathology was aggravated by mutation of 
the E6-AP ubiquitin ligase (Cummings et al., 1999). All these findings point towards 
an involvement of the ubiquitin-proteasome system (UPS) in the pathogenesis of 
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Figure 1: UBB+1 colocalizes with polyglutamine proteins in HD and SCA3.
Staining of paraffin sections of the frontal cortex of HD patients and the pons of SCA3 patients 
for UBB+1 and respectively Htt-07 and α-ataxin-3 (A). Pictures show staining of NIIs with UBB+1, 
distinct from the nucleoli, in both polyglutamine diseases. Magnification bar is 10µm. Double 
stainings show UBB+1 staining in all inclusions positive for 1C2 in juvenile as well as late onset 
HD and SCA3 (B). Magnification bar is 50μm. Note also the cytoplasmic staining for UBB+1 in 
both disorders (A and B).
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polyglutamine diseases and to an enhancement of neurodegeneration by further 
impairment of the UPS (Ciechanover and Brundin, 2003).
We previously reported that, in Alzheimer disease (AD), an aberrant form of ubiquitin 
(UBB+1) accumulates in the neuropathological hallmarks of the disease (van Leeuwen 
et al., 1998). This UBB+1 protein is formed by a dinucleotide deletion (ΔGU), leading 
to a +1 reading frame in the mRNA, and subsequent translation to a protein with 
an aberrant C-terminus. Thus far UBB+1 protein has been found in the hallmarks of 
several neurodegenerative diseases, including AD and other tauopathies, whereas it 
was not detected in synucleinopathies and young control patients without pathology 
(Fischer et al., 2003; van Leeuwen et al., 1998). The aberrant transcript however, in 
contrast to the protein, appeared to be present even in young controls. Under normal 
circumstances, neurons can apparently cope with UBB+1, and accumulation of this 
protein reflects proteasomal dysfunction in different neuropathologal disorders 
(Fischer et al., 2003).
In vitro studies have shown that, although UBB+1 can be degraded by the proteasome 
(Fischer et al., 2003; Lindsten et al., 2002), at higher concentrations it inhibits 
proteasomal degradation of cellular proteins and leads to cell death in neuroblastoma 
cells (De Vrij et al., 2001; Lam et al., 2000). In addition, UBB+1 has recently been 
implicated to mediate neurodegeneration via downstream interaction with the E2-
25K ubiquitin conjugating enzyme, which induces amyloid-β neurotoxicity in vitro 
(Song et al., 2003). In this perspective, UBB+1 might accelerate disease progression 
and increase the severity of the disease. Notably, recent reports show that the 
proteasome activity is indeed decreased in AD (Keck et al., 2003; Keller et al., 2000), 
strengthening the idea that UBB+1 accumulation is intimately related to impairment 
of the proteasome (Ciechanover and Brundin, 2003).
Different findings point towards defective protein degradation in polyglutamine 
diseases. We examined post-mortem brain material of HD and SCA3 for the 
accumulation of UBB+1, as a marker for proteasomal impairment. Moreover, we used 
a cellular model for polyglutamine disease to study the contribution of UBB+1 to 
disease progression, i.e. polyglutamine aggregation and cell death. 
Results
To identify NIIs in different brain areas of HD and SCA3, we used antibodies against 
the N-terminal fragment of the huntingtin protein or full length ataxin-3 respectively 
(Figure 1A). In addition, we used an ubiquitin antibody and the 1C2 antibody to 
identify the inclusions. SCA6 showed staining of cytoplasmic aggregates with the 
α1A-subunit antibody (data not shown). 
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Figure 2: UBB+1 colocalizes with expanded polyglutamines in vitro.
HeLa cells co-transfected 
with plasmids with a 
truncated huntingtin 
fragment containing 19, 
38 or 43 glutamine repeats 
(HA-Q-GFP) together 
with constructs for UBB+1 
or UBB+1;K29,48R, were fixed 
4 days post transfection. All 
cells that were transfected 
with the construct 
with 19 glutamines 
showed a diffuse cellular 
polyglutamine staining 
(A; green; left panel). 
Constructs with 38 and 43 
glutamine repeats result in 
the formation of multiple 
polyglutamine aggregates 
(respectively B-C, and D-F; 
green; left column). Co-
transfection with UBB+1 
gave cytoplasmic staining 
for UBB+1 (A-E) (in red; 
middle column) with all 
constructs. In addition, 
UBB+1 co-aggregates 
with the polyglutamine 
constructs Q38 (B and 
C) and Q43 (D and E) 
whereas UBB+1;K29,48R 
only shows cytoplasmic 
staining despite aggregate 
formation of Q43 (F). 
The right column shows 
the overlay of UBB+1 and 
polyglutamine, with faint 
To-Pro nuclear staining in 
blue. Magnification bar is 
10µm.
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With antibodies against the UBB+1 protein, we detected immunopositive NIIs in the 
cortex (Figure 1A) and striatum of all HD patients (N=30). We found accumulation 
of UBB+1 not only in adult-onset patients but already in juvenile HD. Furthermore, 
we detected UBB+1 immunopositive NIIs in all SCA3 patients (N=6), in all the areas 
investigated (Figure 1A). Besides localization to the NIIs, we also found cytoplasmic 
staining for UBB+1 in the affected neurons in HD and SCA3 (Figure 1A). In contrast, 
in the SCA6 patients (N=2) we did not find any UBB+1 staining in the affected regions 
(data not shown). To ascertain whether UBB+1 localizes to all or only a subset of 
NIIs stained with 1C2 we performed double immunofluorescent stainings on tissue 
sections of both HD and SCA3. We found colocalization of polyglutamine proteins 
and UBB+1 in all the inclusions that were found in both HD and SCA3 (Figure 1B). 
Accumulation of UBB+1 is thus not specific for HD but a general phenomenon found 
in polyglutamine diseases.
Besides being a marker for proteasome impairment, in vitro, UBB+1 inhibits the 
proteasome (Lam et al., 2000; Lindsten et al., 2002). Constructs with expanded 
polyglutamine repeats can be used to mimic many of the features of polyglutamine 
diseases in cell lines, including aggregate formation and interaction with other proteins 
(Cummings et al., 1999; de Cristofaro et al., 1999; Hackam et al., 1999; Lunkes and 
Mandel, 1998).
To investigate the impact of UBB+1 protein on aggregate formation we used plasmids 
with a truncated huntingtin fragment containing 19, 38 or 43 glutamine repeats (HA-
Q19-GFP, HA-Q38-GFP and HA-Q43-GFP) in combination with plasmids containing 
either UBB+1 or a lysine mutant of UBB+1 (UBB+1;K29,48R), that does not inhibit the 
proteasome (Lindsten et al., 2002). Co-transfection of UBB+1 with Q19 resulted in 
distribution of Q19 throughout the cells and cytoplasmic staining for UBB+1 (Figure 
2A). However, besides accumulation of UBB+1 in cells with expanded polyglutamine 
proteins we found colocalization with the inclusions of Q38 (Figure 2B and C) and Q43 
(Figure 2D and E). The nuclear localization of the aggregates in these cells was similar 
to what was observed in post-mortem brain material of the different polyglutamine 
diseases. In addition, a number of cells display a clear apoptotic morphology, with 
fragmented nuclei (Figure 2C and E), in agreement with previous findings for UBB+1 
or expanded polyglutamines alone (De Vrij et al., 2001; Lunkes and Mandel, 1998). 
In contrast to UBB+1, after transfection with UBB+1;K29,48R we found no colocalization 
with the aggregating polyglutamines (Figure 2F; Q43). It is remarkable that this latter 
ubiquitin mutant is not incorporated in the inclusions, although cytoplasmic levels 
are higher than for UBB+1 transfected cells (Lindsten et al., 2002). 
For functional characterizations we used neuronally-differentiated human 
neuroblastoma cells (SH-SY5Y) (Encinas et al., 2000). Cell-proliferation markedly 
influences the aggregate formation and cell-death (Yoshizawa et al., 2001), which makes 
differentiated cells a more useful model for functional assays. In our experiments, 
HeLa cells showed comparable aggregate formation, but due to proliferation and 
susceptibility, much lower levels of cell-death (data not shown). 
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Figure 3: UBB+1 induces aggregate formation and preferentially accumulates with expanded 
polyglutamines.
Differentiated SH-SY5Y neuroblastoma cells were lentivirally infected with constructs with 
truncated huntingtin fragments containing 19, 38 or 43 glutamine repeats (HA-Q-GFP) in 
combination with either UBB+1;K29,48R (KR) or UBB+1 (+1). Cells were quantified for aggregate 
formation every 24 hours after infection (A). Note that huntingtin with 19 glutamines does not 
result in the formation of aggregates, resulting in two overlapping lines in this graph. Constructs 
with 38 and 43 glutamines both show a marked increase in the number of aggregate forming 
cells in the presence of UBB+1. Statistical analysis by three-way ANOVA demonstrated a strong 
correlation between the aggregate formation of expanded polyglutamines, the influence of UBB+1 
and the time course (P<0.001). Expression of UBB+1 was quantified 4 days after infection (B). 
The expression of expanded huntingtin fragments causes a preferential accumulation of UBB+1 
in these cells. Statistical analysis by one-way ANOVA showed a highly significant correlation 
between repeat expansion of the huntingtin fragments and the UBB+1 accumulation (P=0.001). 
All experiments were performed in triplicate.
We quantified the aggregate formation after lentiviral transduction of SH-SY5Y 
neuroblastoma cells with polyglutamine vectors in combination with UBB+1 or the 
double lysine mutant of UBB+1 (Figure 3A). The truncated huntingtin fragments 
with 38 or 43 glutamines show a marked increase in aggregate formation under the 
influence of UBB+1 in comparison to UBB+1;K29,48R. Accumulation of UBB+1 causes an 
increase in polyglutamine protein and thus enhances the aggregate formation. For the 
huntingtin fragment with 38 glutamines we even find a doubling of the number of 
aggregate forming cells due to UBB+1 from 4 days on (Figure 3A). Statistical analysis by 
three-way ANOVA confirmed a highly significant correlation between the aggregate 
formation, the influence of UBB+1 and the time course (P<0.001). Immunofluorescent 
stainings furthermore show a preferential accumulation of UBB+1 in the cells with 
the expanded huntingtin fragments (Figure 3B). Quantification of the cells 4 days 
after infection showed a clear increase in the amount of UBB+1 expressing cells upon 
expansion of the polyglutamine repeat (Figure 3B). Statistical analysis by one-way 
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We made cell lysates 6 days after infection and analyzed these by Western blotting 
(Figure 4). Western blots probed with an anti-HA antibody showed, due to UBB+1, a 
threefold increase in SDS-insoluble aggregate fraction at the top of the gel with both 
38 and 43 glutamines (Figure 4A). The amounts of soluble polyglutamine protein 
however, show only a slight increase for all repeat lengths (Figure 4B). The bars 
(Figure 4D) represent the relative amount of aggregates (Figure 4A) after correction 
for β-actin (Figure 4C). Statistical analysis by two-way ANOVA confirmed that UBB+1 
has a pronounced, highly significant synergistic effect on the aggregate formation of 
constructs with 38 and 43 glutamines (P<0.001). 
Figure 4: UBB+1 increases aggregate formation of expanded polyglutamines.
Differentiated SH-SY5Y neuroblastoma cells were lentivirally infected with constructs with 
truncated huntingtin fragments containing 19, 38 or 43 glutamine repeats (HA-Q-GFP) in 
combination with either UBB+1;K29,48R (KR) or UBB+1 (+1), and harvested 6 days after infection. 
Especially with 38 glutamines a marked increase is seen in the SDS-insoluble fraction that is 
retained at the top of the gel when cells are co-infected with UBB+1 (A). The levels of soluble 
polyglutamine protein show a minor increase (B, around 60kD). Panel (C) shows a β-actin 
staining as a loading control. Bars show the relative integrated optical densities of the aggregate 
fraction after correction for loading (D). Statistical analysis by two-way ANOVA showed a strong 
synergistic effect of UBB+1 on aggregate formation by expanded polyglutamines (P<0.001). All 
experiments were performed in triplicate.
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Figure 5: UBB+1 synergistically aggravates polyglutamine-induced cell death. 
Cell death of differentiated SH-SY5Y neuroblastoma cells, as assessed by a cell survival assay 6 
days after infection, with constructs with 19, 38 or 43 glutamines (HA-Q-GFP) in combination 
with UBB+1;K29,48R (KR) as a control or UBB+1 (+1). Polyglutamine-GFP positive cells were analyzed 
by flow cytometry for conversion of red-fluorescent dye (A; representative FACS analysis). Scatter 
plots clearly show the differential distribution of living cells (lower population) and dead cells 
(higher population; bright red-fluorescent). The bars (B) show the percentage of cell death that 
was observed under different conditions. Q19 shows the background percentage of cell death due 
to infection or culturing and no increase was observed in combination with UBB+1;K29,48R (B). 
The horizontal line signifies the percentage of background cell death. A minor increase in cell 
death was observed with expansion of the polyglutamine repeat. Co-infection with UBB+1 caused 
a small increase in cell death of Q19, but a marked increase was observed with constructs of 
both 38 and 43 glutamines. Statistical analysis by two-way ANOVA showed a strong synergistic 
effect of UBB+1 on cell death by expanded polyglutamines (P<0.001). Caspase inhibition with Ac-
DEVD-CHO resulted in a marked decrease of cell-death due to UBB+1 as well as due to expanded 
polyglutamines. Statistical analysis revealed no significant increase in cell-death in comparison to 
the background level. All experiments were performed in triplicate. 
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To investigate the effect of the expression of the different proteins on the viability of 
neuroblastoma cells we performed a cell-survival assay (Figure 5). The scatter plots 
show a representative FACS analysis of the polyglutamine expressing cells (Figure 
5A). Dead cells show a marked increase in red-fluorescence due to conversion of the 
reactive dye (higher population). Cell death due to Q19 represents the background 
level of cell death due to infection and culturing of the cells, whereas Q19 itself is 
not toxic (de Cristofaro et al., 1999). Combination of Q19 with UBB+1;K29,48R, which 
was used as a control, does not affect cell death. Expansion of the polyglutamine 
repeat resulted in a moderate increase in cell death when combined with UBB+1;K29,48R. 
We measured a small but significant increase for the plasmid with 38 glutamines, 
whereas the expansion to 43 caused a significant three-fold increase in cell death. 
Upon addition of UBB+1 a moderate and significant increase in cell death was found 
for the Q19 construct. In contrast to previous experiments (De Vrij et al., 2001), 
lentiviral transduction resulted in only moderate cell death for UBB+1 (Figure 4B) 
due to degradable levels of UBB+1 protein (Fischer et al., 2003). However, UBB+1 
in combination with longer glutamine repeats caused a much more pronounced 
increase in cell death for Q38 as well as for Q43 constructs. Statistical analysis by 
two-way ANOVA confirmed that the combination of UBB+1 with constructs of 38 
and 43 glutamines has a pronounced, highly significant synergistic effect on the cell 
death mechanism (P<0.001). This synergistic effect manifests itself as an increase of 
the absolute effect of UBB+1 on cell death with increasing length of the Hungtingtin 
fragment. Caspase inhibition by Ac-DEVD-CHO resulted in a marked decrease in 
cell-death in our polyglutamine model, indicating that cell death due to UBB+1 as well 
as due to expanded polyglutamines occurs via an apoptotic pathway (Figure 4B). The 
percentage of cell death with caspase inhibitor did not significantly increase above the 
background level.
Discussion
Previously we reported that the accumulation of UBB+1 in tauopathies is a marker for 
proteasomal dysfunction (Fischer et al., 2003). Here we show that this accumulation 
is not only indicative of proteasome impairment, but that UBB+1 apparently also 
contributes to the pathogenesis of polyglutamine diseases. The accumulation of UBB+1 
protein enhances aggregate formation in a cellular model of polyglutamine disease. 
In addition, the toxicity of UBB+1 in combination with expanded polyglutamines is 
not only additive but clearly works synergistically. It thus suggests that both toxic 
proteins somehow intervene with the same or analogous pathways to compromise 
cellular function, and eventually cause cell death. 
Molecular misreading of the UBB gene is a general process that occurs both in 
neurological diseases and in control individuals (Fischer et al., 2003). We performed 
a ligase chain reaction (LCR), as described earlier, to confirm the presence of UBBΔGU 
transcripts in the mRNA from frontal cortex tissue of three different HD patients 
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(data not shown) (Fischer et al., 2003). The GU deletion was present in all HD patients 
tested, indicating that at the level of the mRNA there is no difference between HD 
patients, controls or any of the previously tested neurological diseases (Fischer et al., 
2003). Differences in UBB+1 staining are probably the result of decreased proteasomal 
activity due to disease-related proteins or ageing (Carrard et al., 2002; Fischer et al., 
2003; Keck et al., 2003; Keller et al., 2000; Zhou et al., 2003). Neurological diseases such 
as Parkinson disease, in which impairment of the proteasome is not demonstrated, do 
not lead to UBB+1 accumulation (Fischer et al., 2003; Furukawa et al., 2002). 
Both HD and SCA3 form NIIs, and we demonstrated here that, independent of their 
protein context, huntingtin and ataxin-3 respectively, these aggregates contain UBB+1 
(Figure 1). Moreover, UBB+1 not only localizes to the inclusions; the cytoplasmic 
immunoreactivity for this aberrant protein is increased as well (Figure 1A), indicating 
high protein levels that potentially impair the proteasome. Accumulation of UBB+1 
reflects in vivo proteasomal impairment in the polyglutamine disorders, which is in 
agreement with previous in vitro results (Bence et al., 2001; Chai et al., 1999; Verhoef 
et al., 2002). What is striking is the accumulation of UBB+1 in all tested HD and 
SCA3 patients, irrespective of polyglutamine length and age, showing that UBB+1 can 
already accumulate at a young age (Figure 1B). The high stability of ubiquitinated 
UBB+1 contributes to the accumulation in disease, and it has been suggested that 
even low levels of misreading can result in toxic protein levels (Lam et al., 2000). 
We did not find UBB+1 in SCA6, suggesting proper functioning of the proteasome 
in this channelopathy. Indeed the proteasome has not been implicated in disease 
progression in SCA6, and the inclusions, which are only present in the cytoplasm, are 
not ubiquitinated (Ishikawa et al., 1999).
Although the mechanism by which different cellular proteins are recruited into 
NIIs is unknown, the presence of UBB+1 in NIIs in human tissue and in a cellular 
model implicates a similar mechanism. Accumulation of UBB+1 will probably start 
in the cytoplasm, followed by translocation into the NIIs. Interestingly, we showed 
that ubiquitination on lysine 29 or 48 is not only required for degradation of UBB+1, 
in agreement with previous results (Lindsten et al., 2002), but is also needed for its 
translocation to the inclusions. Polyubiquitin chains of targeted proteins are bound 
to the S6a regulatory subunit of the 19S cap, and it is likely that both the UBB+1 
resistance to degradation and its proteasomal impairment resemble binding to this 
subunit but lack of processing through the 20S core (Lam et al., 2002; Lam et al., 
2000). Components of the proteasome, and especially the 19S cap structure, have 
been shown to be present in NIIs and could thus explain the localization of UBB+1 
into inclusions (Chai et al., 1999; Schmidt et al., 2002). 
In addition to human brain material, we also found accumulation and co-aggregation 
of the proteasome substrate UBB+1 with expanded polyglutamines in a cellular model 
(Figure 2). Moreover, the proteasome inhibitor UBB+1 causes an increase in aggregate 
formation of expanded polyglutamines (Figure 3 and 4). We suggest that inhibition of 
UBB+1 in polyglutamine diseases
59
the degradation machinery is central to development of polyglutamine diseases and 
causes accumulation of different aberrant proteins. 
We demonstrated that, UBB+1 not only increases aggregate formation, but also has 
a synergistic effect on apoptotic cell-death by expanded polyglutamines (Figure 5). 
Ubiquitinated UBB+1 and expanded polyglutamine proteins have been shown to 
inhibit the proteasome in vitro (Bence et al., 2001; Lindsten et al., 2002; Verhoef 
et al., 2002), and we demonstrated here that both factors enhance the effect of the 
other aberrant protein. The mutual decrease of proteasome activity probably leads 
to further accumulation of aberrant proteins, and eventually cell death. The fact that 
ubiquitination of UBB+1 is required for its proteasomal inhibition (Lindsten et al., 
2002), its toxicity (De Vrij et al., 2001) and its contribution to aggregate formation and 
polyglutamine-induced cell death suggests that polyubiquitination is a prerequisite 
for both aggregate formation and cell-death. 
Although the genetic basis of polyglutamine diseases is known, a number of questions 
remain unanswered as to the precise cause of toxicity and whether aggregates are 
either beneficial or toxic (Michalik and Van Broeckhoven, 2003). Even between 
individuals with similar repeat length, there are differences as to the age at onset, 
the progression, and the extent of atrophy (Halliday et al., 1998; McNeil et al., 1997; 
Rubinsztein et al., 1996; Zoghbi and Orr, 2000). Recent reports indicate that genetic 
and familial factors account for a great deal of variation of the age at onset in HD (Li 
et al., 2003; Wexler et al., 2004). Possible candidates include proteasome subunits and 
cellular chaperones (Chan et al., 2002; Willingham et al., 2003) and, as described in 
the present paper, also factors such as UBB+1 can act as modifiers of both the onset 
and severity of the disease. 
From the present study it is evident that UBB+1 not only accumulates in polyglutamine 
diseases, indicating impairment of the proteasome, but probably plays a role in 
neurodegeneration itself. In addition to co-aggregation with polyglutamine proteins, 
ubiquitinated UBB+1 synergistically aggravates polyglutamine-induced aggregate 
formation, and especially cell-death. Targeting of UBB+1 to the proteasome by 
ubiquitination is thereby required for degradation, toxicity and colocalization with 
the NIIs. Consequently, the accumulation of UBB+1 in HD and SCA3 post-mortem 
tissue, in both the inclusions and the cytoplasm of neurons, implicate UBB+1 as 
an aggravating factor in polyglutamine-induced neurodegeneration, and clearly 
identifies an important role for the ubiquitin-proteasome system in polyglutamine 
diseases. These results indicate that proteasomal activation or removal of its blockades 
is a promising avenue for the treatment of polyglutamine diseases.
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Table 1. Clinicopathological information of Huntington, SCA 3 and SCA 6 patients.
Patient 
number













1 11 f 21 1240 21 22 - 84 3 frontal cortex
2 20 f 36 860 21 17 - 86 4 frontal cortex
3 33 f 144 1220 122 20 - 52 3 frontal cortex
4 39 m 10 na 363 15 - 59 4 frontal cortex, striatum
5 40 m 16 1400 124 10 - 41 3 frontal cortex
6 41 f 24 1150 42 16 - 46 3 frontal cortex, striatum
7 49 m 120 1120 186 21 - 51 4 frontal cortex
8 49 f na na 186 17 - 47 3 frontal cortex
9 50 m 4 1230 31 20 - 47 3 frontal cortex
10 51 m 4 1260 2 27 - 45 3 frontal cortex
11 51 f 5 900 14 19 - 46 4 frontal cortex
12 51 f 74 1100 na 15 - 43 3 frontal cortex
13 52 f 20 840 31 16 - 53 4 frontal cortex
14 55 m 24 1250 124 22 - 47 2-3 frontal cortex
15 56 m 32 1250 2 18 - 49 3 frontal cortex
16 57 f 72 1200 162 16 - 43 3 frontal cortex
17 58 f 34 1170 7 24 - 43 3 frontal cortex
18 60 m 12 1200 248 20 - 43 3 frontal cortex
19 60 m na na 35 26 - 47 4 frontal cortex
20 61 f 17 1050 na 17 - 45 3 frontal cortex
21 61 f 24 840 21 21 - 47 4 frontal cortex
22 62 m 12 1200 62 20 - 43 3 frontal cortex
23 63 f 10 1100 58 17 - 45 3 frontal cortex, striatum
24 64 f 60 1080 7 19 - 42 3 frontal cortex
25 66 m 28 1125 78 21 - 40  3-4 frontal cortex
26 66 f na 950 107 20 - 44 3-4 frontal cortex, striatum
27 68 f 12 1130 62 20 - 42 3 frontal cortex
28 69 f 24 na 155 21 - 40 3 frontal cortex
29 69 m 48 1200 62 16 - 42 3 frontal cortex
30 76 m 14 970 81 15 - 46 3 frontal cortex
SCA3*
31 34 m na 1598 28 20 - 75 medulla oblongata
32 51 m 24 1244 21 27 - 72 hippocampus, mesencephalon
33 59 f 12 1290 21 20 - 72 hippocampus, pons
34 62 m 21 1236 21 23 - 70 hippocampus, pons
35 *** 65 m <12 1258 28 27 - 72 pons
36 *** 66 m 14 1220 21 24 - 70 pons
SCA6*
37 69 m 46 1395 28 ** hippocampus, cerebellum
38 76 m 24 1418 120 22 cerebellum
* all cases positive with htt-07, ataxin-3 and A6RPT-C respectively
** not available, but most probably 21 or 22
*** brothers
na - not available




Autopsy material was obtained from the Huntington bank (Leiden University 
Medical Center, The Netherlands) for HD cases, and the Laboratory of Pathology 
East Netherlands (Enschede, The Netherlands) and University Hospital Groningen 
(Groningen, The Netherlands) for SCA cases (for details see Table 1). We analyzed 
striatal tissue from 4 different HD patients and frontal cortex tissue of in total 30 HD 
patients with polyglutamine expansion of various lengths. Furthermore, we examined 
the hippocampus, pons, mesencephalon and medulla oblongata of 6 different SCA3 
patients and the hippocampus and cerebellum of two SCA6 patients. All brain areas 
were fixed in formaldehyde and subsequently embedded in paraffin.
Immunohistochemistry
Paraffin sections (6 µm) were immunohistochemically labeled with different 
antibodies using the peroxidase-anti-peroxidase method with nickel intensification 
as described previously (van Leeuwen et al., 1998). The 1C2 monoclonal antibody 
against expanded polyglutamine repeats (Trottier et al., 1995) (1:10,000; Chemicon, 
Temecula, USA), polyclonal Htt-07 antiserum against the N-terminus of huntingtin 
(1:100)(Maat-Schieman et al., 1999), polyclonal anti-ataxin-3 antibody (1:2000) 
(Paulson et al., 1997) and polyclonal A6RPT-C against the C-terminus of the α1A-
subunit of the voltage dependent Ca channel (1:100) (Ishikawa et al., 1999) were used 
for the detection of the respective disease proteins. UBB+1 was detected using antisera 
against the C-terminal part of the protein (Ubi2A, 1:1000, bleeding 020698 and 
Ubi2+1, 1:1000, bleeding 010994; see references for details on epitope and specificity 
(Fischer et al., 2003; van Leeuwen et al., 1998)).
For double stainings, we subjected paraffin sections to irradiation with a broad 
spectrum lamp for at least 24 hours to reduce autofluorescence (Hol et al., 2003; 
Neumann and Gabel, 2002). We then deparaffinized sections and incubated them 
with the first antibodies overnight in a humid chamber at 4°C. We enhanced the 
UBB+1 signal using the avidin-biotin-complex and tyramine procedure (Kerstens et al., 
1995) (Sigma-Aldrich, St.Louis, USA) and stained with streptavidin-conjugated-Cy5 
(Jackson Laboratories, West Grove, USA). 1C2 was directly visualized using donkey-
anti-mouse-Cy2. Signal specificity was demonstrated by swapping fluorescent dyes and 
omission of primary antibodies to exclude aspecific staining or signal enhancement. 
Images were obtained using a confocal laser scanning microscope (Zeiss 510).
Cell lines:
HeLa cells were cultured in low-glucose Dulbecco’s modified Eagle medium 
containing 10% fetal calf serum, supplemented with 10000 IU/ml penicillin and 10 
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mg/ml streptomycin (all Invitrogen, Grand Island, NY). Cells were cultured on 0.2% 
gelatin-coated glass coverslips in 24-well plates (Nunc, Roskilde, Denmark) 1 day 
before transfection. 
SH-SY5Y neuroblastoma cells (ATCC:CRL-2260) were cultured in high-glucose 
Dulbecco’s modified Eagle medium containing 15% fetal calf serum, supplemented 
with 100 U/ml penicillin and 100 μg/ml streptomycin (all Invitrogen). Cells were 
cultured in 6-well plates (Nunc) 1 day before infection. Caspase inhibition was 
performed by addition of 100 µM Ac-DEVD-CHO (Sigma) to the culture medium 
every two days.
Transfections
We performed transfections with the calcium-chloride method, using 0.5μg plasmid 
DNA of each of the respective plasmids for 24 well plates (Naldini et al., 1996). 
Polyglutamine plasmids containing a truncated huntingtin fragment with different 
polyglutamine repeats (19, 38 and 43) flanked by a HA tag and green fluorescent 
protein (GFP) reporter sequence were provided by Dr. de Christofaro (de Cristofaro 
et al., 1999). Vectors for ubiquitin, UBB+1 and a lysine mutant of UBB+1 in which both 
lysine 29 and 48 are mutated into an arginine residue (UBB+1;K29,48R) were described 
earlier (Lindsten et al., 2002).
Cells were fixed 4 days after transfection and stained for UBB+1 (Ubi3, 1:500, bleeding 
050897 (De Vrij et al., 2001)). Subsequently cells were incubated with donkey-
anti-rabbit-Cy3 (1:200; Jackson laboratories) and ToPro-3 nuclear staining (1:200, 
Molecular Probes, Leiden, The Netherlands). After staining for UBB+1, pictures were 
obtained using a confocal laser scanning microscope (Zeiss 510). 
Infections
cDNAs for UBB+1, UBB+1;K29,48R, HA-Q19-GFP, HA-Q38-GFP and HA-Q43-GFP were 
cloned in the lentiviral transfer plasmid pRRLsin-PPThCMV-GFP-pre (Naldini et al., 
1996). VSV-G pseudotyped lentivirus was produced by cotransfection of the transfer 
plasmid and helper plasmids (pCMVdeltaR8.74 and pMD.G.2) in 293T cells. Medium 
was harvested 24 and 48 h after transfection and concentrated by ultracentrifugation. 
Virus pellets were resuspended in PBS containing 0.5% bovine serum albumin 
(Sigma). Stocks were titered with a HIV-1 p24 coat protein ELISA (NEN Research, 
Boston, USA). Lentiviral vectors were used to infect SH-SY5Y neuroblastoma cells at 
a multiplicity of infection of 50. 
Quantification of cells
For aggregate formation, cells were counted manually at different time intervals after 
infection. The number of aggregate forming cells was quantified in three randomly 
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selected fields per experiment. Experiments were performed in triplicate and 
statistics was performed using three-way ANOVA, testing the interaction between 
repeat expansion, UBB+1 protein expression and time course. UBB+1 immunopositive 
cells, were counted after fixation and immunofluorescent staining for UBB+1. The 
number of UBB+1 immunopositive cells were quantified in three randomly selected 
fields per experiment. Experiments were performed in triplicate and statistics was 
done using one-way ANOVA, testing the significance of repeat expansion on UBB+1 
accumulation.
Western blots
We harvested neuroblastoma cells (SH-SY5Y) 6 days after infection in cold PBS. 
Cell-pellets were resuspended in lysis-buffer (1% NP40, 0.1 M NaCl, 0.01 M Tris-
HCl pH 8.0, 1 mM EDTA pH 8.0) containing protease inhibitors; 100 mM PMSF 
and 10 mg/ml leupeptin. We performed cell-lysis at 4°C for 30 minutes and passed 
samples through a 25G needle to ensure complete lysis. All samples were loaded onto 
SDS-PAGE gels and transferred semi-dry onto nitrocellulose (Schleicher & Schuell, 
Dassel, Germany). Polyglutamine proteins were detected using a monoclonal antibody 
directed against the HA tag (12CA5, 1:100, culture supernatant) (Field et al., 1988). 
Blots were additionally probed with a monoclonal β-actin antibody (JLA2.0, 1:500; 
Developmental Studies Hybridoma Bank, Iowa, USA) as a control for the amount of 
cell-lysate loaded. Subsequently, blots were incubated with anti-mouse HRP (1:1000; 
DAKO, Glostrup, Denmark) followed by Lumilight ECL (Perkin Elmer, Norwalk, 
USA) chemiluminescence. The integrated optical density of the bands was determined 
by image analysis with Image Pro Plus.
Cell survival assay
We assessed SH-SY5Y cell-survival using a Life-Dead® kit (red fluorescence; Molecular 
Probes, Leiden, The Netherlands) and analyzed on a flow cytometer (Becton 
Dickinson, Palo Alto, USA) according to the manufacturers protocol. In short, we 
harvested lentivirally infected cells (see before) 6 days after infection, washed in PBS 
and incubated them for 30 minutes with the fluorescent reactive dye. Subsequently, 
we fixed cells with 4% formaldehyde for 15 minutes and resuspended in PBS-BSA 
(1x PBS pH-7.6, 0.5% BSA, 0.1% NaN3). We analyzed polyglutamine-GFP expressing 
cells by flow cytometry for conversion of the Life-Dead® kit reactive dye. At least 104 
polyglutamine-GFP positive cells were examined per sample. Dead cells showed a 
marked increase of red-fluorescence over living cells due to conversion of the dye 
(Figure 4A). Experiments were performed in triplicate and statistics were done using 
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Abstract
UBB+1, a mutant form of ubiquitin, is a substrate and an inhibitor of the proteasome 
which accumulates in the neuropathological hallmarks of Huntington disease 
(HD). In vitro, expression of UBB+1 and mutant huntingtin synergistically increase 
aggregate formation and polyglutamine induced cell death. We generated a UBB+1 
transgenic mouse line expressing UBB+1 within the neurons of the striatum. In these 
mice lentiviral driven expression of expanded huntingtin constructs into the striatum 
results in a significant increase in neuronal inclusion formation. Although UBB+1 
transgenic mice show neither a decreased lifespan nor apparent neuronal loss, they 
appear to be more vulnerable to toxic insults like expanded polyglutamine proteins 
due to a modest proteasome inhibition. These findings underscore the relevance of an 
efficient ubiquitin-proteasome system in HD.
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Introduction
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder 
that is caused by the expansion of a CAG trinucleotide (polyglutamine) repeat in 
the huntingtin gene. All polyglutamine expansion disorders are characterized by 
progressive neuronal dysfunction starting around mid-life and show an inverse 
correlation between polyglutamine repeat length and age at onset (Zoghbi and Orr, 
2000). Expansion of this repeat in the huntingin protein to over 36 consecutive 
glutamines results in aberrant folding with a consequential toxic gain of function of 
the mutant protein. In HD, neuronal degeneration is particularly visible in the corpus 
striatum (cs) resulting in severe atrophy (Halliday et al., 1998). In addition to the repeat 
expansion there are other factors, including proteasomal activity and expression or 
recruitment of cellular chaperones, which could influence polyglutamine toxicity and 
disease development (Wexler et al., 2004).
Neuronal intranuclear inclusions (NIIs) of expanded polyglutamine protein are the 
most prominent pathological hallmark of polyglutamine diseases (DiFiglia et al., 
1997). In HD, the huntingtin gene is cleaved to result in an N-terminal fragment 
containing the polyglutamine repeat, which is found in the inclusions (Sieradzan et al., 
1999). Although recent observations point towards a protective role for formation of 
large inclusions, NIIs are still believed to correlate to toxic protein levels and severity 
of disease (Arrasate et al., 2004; Ross and Poirier, 2004).
The ubiquitin proteasome system (UPS) has been widely implicated in 
neurodegenerative diseases (Schwartz and Ciechanover, 2009). In HD, impairment of 
the proteasome has been suggested to affect disease progression and this involvement 
is reflected by localization of ubiquitin and components of the UPS to NIIs (DiFiglia 
et al., 1997; Schmidt et al., 2002). Furthermore, expanded polyglutamine proteins 
have been shown to directly inhibit the proteasome and lead to the upregulation of 
poly-ubiquitinated proteins that are targeted for degradation (K48 linked) (Bence et 
al., 2001; Bennett et al., 2007).
An aberrant form of ubiquitin (UBB+1) was found to accumulate in the hallmarks 
of HD and spinocerebellar ataxia 3 (de Pril et al., 2004; Fischer et al., 2003). UBB+1 
can no longer ubiquitinate substrate proteins, and was shown to be a reporter for 
proteasomal dysfunction (Fischer et al., 2003). Although UBB+1 can be ubiquitinated 
and degraded by the proteasome, at higher concentrations it also inhibits proteasomal 
degradation of cellular proteins and leads to cell death in neuroblastoma cells (van 
Tijn et al., 2007). To investigate the effect of UBB+1 expression in vivo, we generated 
transgenic mice neuronally expressing UBB+1 in different areas of the brain, including 
the striatum (Fischer et al., 2009). Even though no overt atrophy or degeneration was 
observed in these mice, proteasome activity in the cerebral cortex is decreased to 
about 80% of wild-type levels.
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Figure 1: UBB+1 localizes to Huntingtin inclusions in human caudate nucleus of the corpus 
striatum. 
Staining for 1C2, against expanded polyglutamine protein, and UBB+1 present NIIs in the cs of a 
HD patient (#4). For details see (de Pril et al., 2004). Scale bar is 20 μm.
Figure 2: Unilateral injection of UBB+1 transgenic line 3413 and wildtype littermates.
Coronal 50 μm vibratome section of a line 3413 UBB+1 transgenic displaying the injection site (A) 
and overview of the HD-Q43 injection in the striatum(B).
Aggregate formation in UBB+1 mice
71
Previously, we found an increased aggregate formation and aggravation of 
polyglutamine induced cell death mediated by UBB+1 in vitro (de Pril et al., 2004). 
Furthermore, we detected UBB+1 protein expression in NIIs within the cs and cortex 
in post mortem brain material of HD. Therefore the aim of this study was to investigate 
the influence of UBB+1 on aggregate formation in vivo and test whether a modest 
proteasomal inhibition has a significant impact on the neuropathology of HD.
Results
The main pathological changes in HD manifest primarily within the neurons of the cs 
and frontal cortex. Within the striatum, severe atrophy is observed resulting in only a 
small set of neurons that remain which display NIIs. In parallel with the frontal cortex 
(de Pril et al., 2004), we find that NIIs in the cs accumulate aberrant ubiquitin along 
with the expanded polyglutamine protein (Figure 1). Both the 1C2 antibody, raised 
against expanded polyglutamine (Trottier et al., 1995), and UBB+1 antibodies identify 
inclusions in HD sections. Since the cs is the most severely affected area in HD we 
selected this area for our in vivo study.
UBB+1 transgenic mice line 3413 express UBB+1 under the CamKIIα promoter, and show 
transgene expression in neurons in the cortex, hippocampus, amygdala and striatum 
(Fischer et al., 2009). We performed unilateral injections in the striatum of male, 
6-month old UBB+1 transgenic mice and wild-type littermate controls with lentiviral 
vectors encoding a GFP-tagged huntingtin fragment containing a pathological repeat 
of 43 glutamines (HD-Q43; Figure 2). As control, we used a similar lentiviral vector 
encoding a non-pathological repeat length of 19 glutamines (HD-Q19). To identify 
the neuronal cell population expressing UBB+1, tissue sections were stained with the 
neuron specific marker NeuN and anti-UBB+1.
At 10 days after injection, expression of non-pathogenic HD-Q19 in the striatum 
leads to cytoplasmic localization of the protein in both the 3413 line as well as 
their wildtype littermates (not shown). On the other hand, lentiviral expression of 
the expanded HD-Q43 resulted in the formation of NIIs at 10 days after injection 
in both wildtype (Figure 3A) and transgenic mice (Figure 3B). We observed clear 
expression of huntingtin-GFP fusion protein in neurons within a range of 400 μm 
surrounding the injection site (Figure 2B) and did not observe differences between 
line 3413 and wild-type littermates in the number of transduced cells (Table 1). As 
we did not use a neuron-specific promoter or viral backbone, GFP expression was 
also detected in astrocytes and oligodendrocytes. These non-neuronal cells do not 
express the UBB+1 transgene under the CamKIIa promoter and were excluded from 
the analysis. However, it can be clearly observed from the images, as shown in Figure 
4, that these cells express higher levels of HD-Q43 compared to the neuronal cell 
population and therefore appear more prone to aggregate formation (Figure 2A; 
arrowheads). In vitro studies have indeed shown that aggregate formation is cell type 
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Figure 3: Expanded huntingtin expression in the striatum of mouse line 3413. 
UBB+1 transgenic line 3413 and their wild-type littermates were injected with lentiviral HD-
Q43-GFP (green) constructs into the striatum. Mice were sacrificed at 10 (A, B) and 22 days (C, 
D) post injection and stained for neuronal marker NeuN (red) and the UBB+1 transgene (blue). 
Representative images are shown of all groups displaying marked aggregate formation from 10 
days onwards. The arrows show examples of NIIs within the neurons. In line 3413, we find that 
the neurons express UBB+1 and part of the transduced cells show aggregate formation of HD-Q43 
(B; arrows). Magnifications of inserts clearly show NII formation in the striatum of injected mice. 
Arrowheads indicate high expression levels and aggregate formation in non-neuronal cells that do 
not express UBB+1. Scale bar is 20 μm.
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specific and influenced by expression levels of polyglutamine proteins resulting in 
extensive aggregate formation in astrocytes and oligodendrocytes (Yoshizawa et al., 
2001). 
We quantified the formation of NIIs in image stacks through the tissue sections of the 
striatum, as shown in Table 1. In addition, we assessed the number of neurons with 
cytoplasmic expression of HD-Q43. We found a highly significant (2.2-fold) increase 
in the percentage of UBB+1 positive neurons showing inclusion formation already at 
10 days post injection (Table 1 and Figure 4; P<0.001). These results demonstrate that 
UBB+1 transgenic mice show a marked decrease in their ability to degrade aberrant 
polyglutamine protein. Also the percentage of neurons displaying multiple aggregates 
was markedly enhanced in transgenic animals compared to the wildtype littermates 
(5.2-fold; P<0.001), showing that the neurons in the transgenic mice are much more 
vulnerable to protein accumulation. 
22 days after HD-Q43 injection, we observed an increase in the number of NIIs 
compared to 10 days in wild type as well as transgenic mice (Table 1; Figure 4). The 
percentage of neurons displaying inclusions increased to over 70% for the transgenic 
animals, in contrast to approximately 33% for the wildtype littermates, which is still 
4% lower than the transgenic animals at 10 days. Altogether, line 3413 demonstrates a 
significant increase in the formation of aggregates compared to wild type littermates at 
22 days (P=0.01) as well as over time (P<0.001). The number of neurons with multiple 
aggregates also showed a significant increase to 14%, compared to wild type animals at 
22 days (P<0.01). It appears that wild type animals are able to cope differently with the 
toxic polyglutamine protein compared to UBB+1 transgenics, and that the inclusions 
are formed in a more organized manner, i.e. not distributed over the cell, but rather 
localized in single inclusion bodies (Figure 3).
Discussion
Our results demonstrate the importance of the role the UPS plays in the pathogenesis 
of neurodegenerative disorders such as HD. Our previous findings that UBB+1, which 
accumulates in NIIs in HD and SCA3 patients, aggravates both polyglutamine induced 
cell-death as well as aggregate formation in a cell culture model (de Pril et al., 2004) 
emphasized the relevance of protein homeostasis in polyglutamine diseases. Here, 
we demonstrate that efficient UPS function is equally important in an in vivo model, 
showing increased polyglutamine aggregate formation in the UBB+1 transgenic line. 
Transgenic mice line 3413 postnatally express UBB+1 in neurons, leading to a reduction 
in cortical proteasome activity (down to 80% of wild-type levels) accompanied by an 
altered proteomic profile that resembles the changes observed in Alzheimer’s disease 
(AD) (Fischer et al., 2009). Strikingly, UBB+1 transgenic mice show a normal life-
span, and absence of classical neuropathology. These data suggest that UBB+1, which 
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induce neuropathology by itself. We clearly show here that in the presence of a second 
insult such as polyglutamine expression, UBB+1-mediated proteasome inhibition leads 
to an exacerbated neuropathology.
Differences in UPS efficiency or the level at which aberrant proteins like UBB+1 
accumulate could account for the inter-patient variation in disease onset or extent 
of atrophy of HD (McNeil et al., 1997; Wexler et al., 2004). Expanded polyglutamine 
proteins lead to the accumulation of substrate proteins that are targeted for proteasomal 
degradation showing in vivo evidence of UPS inhibition in HD (Bennett et al., 2007). 
However, these accumulated proteins do show proper ubiquitination, hence the 
ubiquitination machinery does not appear to be affected. In vitro experiments have 
shown that aberrant proteins such as expanded polyglutamine and UBB+1 are difficult 
to degrade and thereby inhibit the proteasome (Bence et al., 2001; van Tijn et al., 2007). 
In HD, a reduction in proteasome activity was observed in all affected brain regions as 
well as an inability to activate the proteasomes that are present (Seo et al., 2004). This 
proteasomal inhibition by expanded polyglutamine proteins results in accumulation 
of other aberrant proteins which could account for the synergistic effect that we 
found in UBB+1 transgenic mice. In HD transgenic mouse line R6/2 no alteration in 
UPS activity could be detected although an upregulation of 20S activity was found 
in response to expanded huntingtin expression (Bett et al., 2009). Interestingly, the 
increase in 20S activity might correlate with activation of UPS activity in response to 
cellular stress in contrast to long time exposure to expanded polyglutamine proteins 
in symptomatic HD patients. The addition of other cellular stressors such as UBB+1 
is therefore likely to better represent the disease phenotype that is found in patients 
and which might be aggravated by normal human ageing resulting in mid-life onset 
of HD in patients. 
A mere 20% reduction in UPS activity in line 3413 resulted in a more than 2-fold 
induction in the number of NIIs. As NII appear to be protective in in vitro studies 
(Arrasate et al., 2004), we can not exclude this as a contributing factor in the observed 
increase in NII formation in UBB+1 transgenic mice. The clear effect of UPS inhibition 
by UBB+1 on polyglutamine aggregation makes it unlikely to be accounted for by more 
efficient protein storage at equal expression levels of huntingtin. Also the increase in 
multiple aggregates per cell does argue against protective aggresomes. Increased levels 
of expanded huntingtin, as a result of UPS inhibition by aberrant ubiquitin, are likely 
to result in increased aggregate formation in parallel with increased pathology as also 
observed in juvenile HD (Maat-Schieman et al., 1999).
Although we can not resolve the consequential accumulation of aberrant proteins, 
subtle differences, also in their expression, can play a role in the start of this deleterious 
process and affect the onset of disease. These findings underline the importance of 
the UPS for neurodegenerative disorders. Decreased proteasome activity disturbs 
the cellular machinery of protein homeostasis whereby target proteins are no 
longer efficiently degraded. The consecutive further increase of aberrant proteins 
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Figure 4: UBB+1 transgene expression increases aggregate formation of expanded 
huntingtin.
Neuronal aggregate formation of HD-Q43-GFP was quantified at 10 and 22 days post injection. 
NeuN-positive cells were scored for cytoplasmic localization respectively aggregation of expanded 
huntingtin A significant increase was found in the number of NIIs that are formed in the UBB+1 
transgenic mice at 10 and 22 days after injection compared to wildtype animals as well as in time 
(* P<0.001; ** P=0.01). Also the number of neurons with multiple aggregates showed a marked 
increase (P<0.01).
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may eventually lead to neuronal death. Potentially, by disturbing the capacity of the 
UPS, other pathways involved in aberrant protein metabolism may be activated. 
Interestingly, impairment of the UPS in a Drosophila model of spinobulbar muscular 
atrophy resulted in a compensatory increase in autophagy to rescue aberrant protein-
induced neurodegeneration (Pandey et al., 2007). It will be interesting to further 
evaluate the consequence of UBB+1 expression on the neuropathological changes in 
HD by crossing line 3413 with HD transgenic mouse lines. Double transgenics will 
more closely relate to the actual HD phenotype and enable a further investigation of 
the influence of an impaired UPS on HD development.
Materials and Methods 
Mice
Male 6 month old mice of line 3413 (Fischer et al., 2009) were used in this study. 
For Q19 injections 2 mice were injected of every group. For expanded huntingtin 
constructs (Q43) 3 mice were used for all groups. Injected groups of line 3413 and 
littermate controls were sacrificed 10 or respectively 22 days after transduction. Mice 
were kept in group housing on a 12/12 h light-dark cycle with food and water ad 
libitum in specific pathogen free conditions. All animal experiments were performed 
conforming to national animal welfare law and under guidance of the animal welfare 
committee of the Royal Netherlands Academy of Arts and Sciences.
Striatal transductions
Mice were anesthetized with 10 ml/kg FFM (0.0787 mg/ml fentanyl citrate, 2.5 mg/ml 
fluanisone, 0.625 mg/ml midazolam in water). The skull was exposed and coordinates 
for infusion (1.0 mm anterior-posterior, -2.2 mm lateral; figure 2A) were read against 
bregma (Paxinos and Franklin, 2001). A hole was drilled through the skull, and the 
dura was punctured. An 80 μm glass needle was inserted 3.2 mm into the brain and 
1*109 transducing units of virus was injected in a total volume of 1 μl. Production 
of htt-GFP lentivrial vectors has been described in (de Pril et al., 2004). The skin 
was sutured, mice were administered 0.05 μg/g buprenorphine intramuscular as an 
analgesic and 10 μl/g 0.9% NaCl subcutaneously to prevent de-hydration. Mice were 
kept at 37°C until they had recovered, subsequently they were housed individually to 
prevent opening of the sutures.
Immunohistochemistry
Animals were given deep pentobarbital anesthesia (i.p.) and were perfused intra-
cardially with phosphate-buffered saline (PBS) followed by PBS containing 4% 
paraformaldehyde. Brains were cut on a sectioning vibratome in 50 micron thick 
sections. Slices were stained free floating with rabbit polyclonal anti-UBB+1 (Ubi3 
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serum; 1:1000) and monoclonal NeuN (Chemicon; 1:400) diluted in Supermix (50 
mM Tris, 150 mM NaCl, 0.25% gelatin and 0.5% Triton X-100, pH 7.4), followed by 
Cy5 and Cy3 staining (Jackson ImmunoResearch; 1:800) Nuclei were visualised with 
TO-PRO-3 (Molecular Probes; 1:1000). Subsequently, slices were mounted in mowiol 
(0.1 M Tris-HCl pH 8.5, 25% glycerol, 10% w/v Mowiol 4-88) images were acquired 
using confocal laser scanning microscopy (Zeiss 510) and accompanying software 
(Zeiss LSM Image Browser).
Quantification of transductions
Image stacks (5-7 per animal) were obtained by sectioning through the brain slices 
at 2 μm apart to obtain an optimal resolution. Transduced neurons were quantified 
on the basis of NeuN positive staining and GFP signal. Inclusions were qualified 
as clearly distinct protein accumulations of GFP tagged polyglutamine protein. 
Quantifications were performed blinded with respect to genotype of the mice and 
statistics was performed using two-way Anova. Neuronal aggregates were counted 
manually through these sections, blinded with respect to the genotype.
Acknowledgements
We thank Drs. M.L. Maat-Schieman (Department of Neurology, Leiden University 
Medical Center, Leiden, The Netherlands) for tissue sections and G. de Fluiter, M. 
Cozijnsen, G. Adema, L. Vis and C. Levelt (Netherlands Institute for Neuroscience) for 
animal care, T. de Christofaro (Universita di Napoli, Italy) for sending of polyglutamine 
plasmids and L. Naldini (Institute for Cancer Research, Italy) for lentiviral plasmids. 
Financial support was given by the Prinses Beatrix Foundation (MAR 99-0113), the 
ISAO/IARF grants 01504, Matty Brand Stichting and Hersenstichting Nederland 
(13F05.11 15F07(2).48 and 2008(1).17).
Chapter 5
Ubiquitin-conjugating enzyme E2-25K / Hip-2 increases aggregate 
formation and cell death in polyglutamine diseases
Remko de Pril, David F. Fischer, Raymund A.C. Roos and Fred W. van Leeuwen
Mol Cell Neurosci 34: 10-19

E2-25K in Huntington disease
81
Abstract
Polyglutamine diseases are characterized by neuronal intranuclear inclusions of 
expanded polyglutamine proteins, which are also ubiquitinated, indicating impairment 
of the ubiquitin proteasome system. E2-25K (Hip2), an ubiquitin-conjugating 
enzyme, interacts directly with huntingtin and may mediate ubiquitination of 
the neuronal intranuclear inclusions in Huntington Disease. E2-25K could thus 
modulate aggregation and toxicity of expanded huntingtin. Here we show that E2-
25K is involved in aggregate formation of expanded polyglutamine proteins and 
polyglutamine-induced cell death. Both a truncated mutant, lacking the catalytic tail 
domain, as well as a full antisense sequence, reduce aggregate formation. Strikingly, 
both E2-25K mutants also reduced polyglutamine-induced cell death. In post-
mortem brain material of both Huntington Disease and SCA3, E2-25K staining of 
polyglutamine aggregates was observed in a sub-set of neurons bearing intranuclear 
neuronal inclusions. These results demonstrate that targeting by ubiquitination plays 
an important role in the pathology of polyglutamine diseases. 
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Introduction
Several neurodegenerative diseases have been shown to be caused by the pathogenic 
expansion of a polyglutamine repeat, including the Spinocerebellar ataxias (SCAs) and 
Huntington disease (HD) (Nakamura et al., 2001; Zoghbi and Orr, 2000). Expansion of 
the repeat above a critical length results in severe neurodegeneration accompanied by 
the pathological formation of neuronal intranuclear inclusions (NIIs) in the affected 
areas of the brain (DiFiglia et al., 1997). Although there is still an ongoing debate 
as to whether these inclusions are detrimental, accumulating evidence points to the 
favourable formation of large aggregates as a means of sequestering these aberrant 
proteins (Arrasate et al., 2004; Saudou et al., 1998). However, since the aggregation 
prone properties of these proteins are the underlying cause of the disease (Perutz et 
al., 1994; Scherzinger et al., 1997), presumably an early stage of aggregate formation 
initiates toxicity.
Several studies have implicated the ubiquitin-proteasome system (UPS) in the 
pathogenesis of polyglutamine diseases and demonstrate an enhancement of 
neurodegeneration by further impairment of the UPS (reviewed by (Ciechanover and 
Brundin, 2003)). The fact that NIIs incorporate ubiquitin or ubiquitinated proteins 
indicates that the aggregating proteins are targeted to, but not efficiently degraded 
by, the proteasome (DiFiglia et al., 1997; Paulson et al., 1997). In vitro studies have 
furthermore shown that expanded polyglutamines can directly inhibit the proteasome 
(Bence et al., 2001; Verhoef et al., 2002), resulting in apoptotic cell death (de Pril et al., 
2004; Li et al., 2000). In addition, in SCA3 patients, subunits of the 26S proteasome 
have been shown to be recruited to NIIs (Chai et al., 1999; Schmidt et al., 2002). 
Finally, in SCA1 transgenic mice, the Purkinje cell pathology was aggravated by 
mutation of the E6-AP ubiquitin ligase although the number of NIIs was reduced 
(Cummings et al., 1999). 
Recently, we reported that an aberrant form of ubiquitin (UBB+1) accumulates in the 
NIIs and the cytoplasm of neurons within the affected areas of HD and SCA3 (de Pril 
et al., 2004). The accumulation of UBB+1 in post-mortem brain material of different 
neuropathological disorders acts as a marker for proteasomal impairment (de Pril et 
al., 2004; Fischer et al., 2003). Moreover, we demonstrated that UBB+1, being a substrate 
and an inhibitor of the proteasome, enhances aggregation of expanded polyglutamine 
proteins and synergistically aggravates polyglutamine-induced cell death. These 
findings demonstrate the importance of an efficient UPS in neurodegenerative 
diseases such as the polyglutamine disorders.
Ubiquitin-conjugating enzyme E2-25K (or Hip2; Huntingtin interacting protein 2) is 
highly expressed in the brain and was found in a yeast two-hybrid screen to interact 
with huntingtin in a repeat-independent matter (Kalchman et al., 1996). Recently, E2-
25K has been implicated in the mediation of amyloid-β neurotoxicity and proteasome 
inhibition in vitro (Song et al., 2003). Despite the interaction with huntingtin and the 
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Figure 1: E2-25K colocalizes with polyglutamine aggregates in dead cells.
Differentiated SH-SY5Y neuroblastoma cells were lentivirally transduced with truncated 
huntingtin constructs containing 19 or 43 glutamine repeats (Qxx-HTT-GFP). A cell death assay 
was performed 4 days post transduction. Cells were subsequently fixed and stained for endogenous 
E2-25K. Cells that are transduced with the Q19-HTT-GFP construct show a diffuse cytoplasmic 
staining for E2-25K (A; blue; panel 2) and cytoplasmic localization of Q19-HTT-GFP (green; left 
panel). Upon transduction with Q43-HTT-GFP we once more find cytoplasmic staining for E2-
25K (B-D; blue panel 2) and the formation of aggregates of expanded polyglutamines (green; left 
panel). Cells that are subject to expanded polyglutamine induced cell death (red; panel 3; cell death 
reporter) show upregulation or nuclear translocation of E2-25K and coaggregation of the enzyme 
with the expanded polyglutamine proteins (closed arrowheads). Normally, even cells with a high 
aggregate load (C) do not show coaggregation of E2-25K. Occasionally we do find aggregates 
that are positive for E2-25K and are not stained by the cell death fluorescent reagent (D; open 
arrowheads) suggesting that upregulation or nuclear translocation and consecutive coaggregation 
is one of the events preceding apoptosis. Staining for p53 shows diffuse staining in most cells and a 
clear colocalization with the cell death reporter (E).The right column shows the overlay of E2-25K 
(or p53), cell death and poly-Q. Magnification bar is 50 µm.
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importance of E2-25K as part of the UPS machinery, there have been no reports on 
the influence of E2-25K on HD or even its sub-cellular localization in this disease. 
In the present paper we studied the role of E2-25K in aggregate formation and cell 
death in polyglutamine disease. 
Results
We used neuronally differentiated SH-SY5Y cell lines, which were transduced with 
a lentiviral vector expressing a truncated huntingtin fragment containing 19 or 43 
glutamine repeats. Staining of these cells for endogenous E2-25K showed a diffuse 
cytoplasmic staining in all cells (Figure 1A-D; panel 2). However, we noticed that, 
although E2-25K did colocalize in some of the aggregates, this was not the case for 
all aggregate-forming cells. The morphology of these cells suggested that this might 
reflect the viability of the cells and lead us to perform a cell death assay. Surprisingly, 
it appeared that the ubiquitin-conjugating enzyme E2-25K was found in the 
aggregates primarily in the cells that were in the process of dying (Figure 1B-D; closed 
arrowheads). Occasional colocalization of E2-25K with the polyglutamine aggregates 
in living cells, suggests that the upregulation or nuclear translocation of E2-25K and 
its subsequent colocalization with polyglutamine aggregates, precedes cell death 
(Figure 1D; open arrowheads). However, using Western blot analysis we were unable 
to demonstrate an obvious upregulation of the enzyme over the entire population of 
cells (data not shown). Staining for the tumour suppressor protein p53 demonstrates a 
clear upregulation and colocalization with the cell death reporter (Figure 1E). Indeed, 
p53 has been shown to play an important role in determining whether a cell will 
go into apoptosis and has been shown to coaggregate with polyglutamine inclusions 
(Levine, 1997; Steffan et al., 2000; Suhr et al., 2001).
To test the influence of E2-25K on aggregate formation and cell-viability we constructed 
lentiviral vectors containing either the full length E2-25K enzyme, the enzyme lacking 
its C-terminal catalytic domain or the complete anti-sense sequence. These constructs 
were cotransduced with the truncated huntingtin fragments. The E2-25K protein 
contains a tail region that is necessary for the generation of K48 linked polyubiquitin 
chains (Haldeman et al., 1997). The E2-25K protein lacking its tail region still interacts 
with ubiquitin activator E1. Expression of the truncated enzyme will thus compete 
for activated ubiquitin without tagging target proteins for degradation. Furthermore, 
the full anti-sense sequence of the E2-25K mRNA has been shown to be sufficient to 
knock down the expression of E2-25K in cell lines (Song et al., 2003).
We quantified the aggregate formation after lentiviral transduction of SH-SY5Y 
neuroblastoma cells with polyglutamine vectors in combination with one of the E2-
25K vectors. The truncated huntingtin fragment with 43 glutamines fused to green 
fluorescent protein (Q43-HTT-GFP) shows a marked time-dependent increase 
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Figure 2: E2-25K mediates aggregate formation of expanded polyglutamines.
Differentiated SH-SY5Y neuroblastoma cells were lentivirally transduced with constructs with 
truncated huntingtin fragments containing 19 or 43 glutamine repeats (Qxx-HTT-GFP) in 
combination with either E2-25K, a truncated Δtail mutant, or the full antisense sequence. Cells 
were quantified for aggregate formation every 24 hours after transduction. Upon addition of E2-
25K there is no significant increase in aggregate formation of Q43-HTT-GFP, probably due to 
sufficient levels of endogenous E2-25K in the cells. Addition of either the Δtail mutant or the 
antisense sequence of E2-25K results in a highly significant decrease in aggregate formation. E2-
25K clearly mediates the ubiquitination and subsequent aggregate formation of the expanded 
polyglutamines. Statistical analysis by three-way ANOVA confirmed that the combination of E2-
25K with constructs of 43 glutamines has a pronounced, highly significant effect on the aggregate 
formation in time *P<0.001.
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in aggregate formation compared to the Q19-HTT-GFP construct (Figure 2). Co-
transduction with the E2-25KΔtail mutant or with the antisense sequence reduces 
the aggregate formation of Q43-HTT-GFP, compared to a mock-treated condition or 
with addition of E2-25K (P<0.001). Co-transduction of Q43-HTT-GFP with E2-25K 
did not enhance aggregate formation; apparently the levels of endogenous E2-25K are 
not rate-limiting for aggregate formation.
Since it is still under debate whether aggregate formation is either beneficial or 
detrimental we measured the viability of the cells. As we showed previously there is 
a low level of cell death due to viral transduction and culturing that is represented by 
the levels of Q19-HTT-GFP (de Pril et al., 2004). Here we found that co-expression of 
E2-25K and Q19-HTT-GFP does not result in an effect on cell death (Figure 3B). Co-
expression of either the Δtail mutant or the antisense sequence with Q19-HTT-GFP 
neither had an effect on these levels. 
As we have shown previously, expansion of the polyglutamine repeat results in 
a marked increase in cell death (de Pril et al., 2004). Overexpression of E2-25K in 
combination with Q43-HTT-GFP does not increase cell death, as was also seen 
for aggregate formation. Co-expression of either the Δtail mutant or the antisense 
sequence with Q43-HTT-GFP however resulted in a significant decrease in the levels 
of cell death (Figure 3B; P<0.05). Inhibition of E2-25K thus results in a reduction of 
expanded polyglutamine toxicity to background levels. 
We found that E2-25K has a role in both aggregate formation and cell death by 
expanded polyglutamine proteins and colocalizes in aggregates in a cell-culture 
model. To reveal whether these findings are relevant for Huntington Disease, and for 
other polyglutamine diseases, we stained post mortem brain material of both HD and 
Spinocerebellar Ataxia type 3 (SCA3) for E2-25K reactivity. All patient material was 
characterized previously and found to be immunopositive for ubiquitin, the UBB+1 
protein, and for the respective expanded polyglutamine proteins (see Table 1 of (de 
Pril et al., 2004)). We found that a fraction of NIIs in all cases of both HD (Figure 4A-C; 
closed arrowheads) and SCA3 (Figure 4D) were immunopositive for E2-25K. To our 
knowledge this is the first evidence that E2-25K is indeed localized in the inclusions 
in polyglutamine diseases. Double staining of the polyglutamine antibody 1C2 with 
E2-25K shows that, in contrast to many cellular proteins that reportedly coaggregate 
in all NIIs (Mitsui et al., 2002), E2-25K is not found in all the inclusions (Figure 4C; 
open arrowhead). The presence of E2-25K in part of the NIIs indicates a differential 
mechanism that might reflect the disease state of the respective aggregate bearing 
neurons. This finding corresponds to our in vitro observations, that co-aggregation 
of E2-25K with polyglutamine aggregates marks cell death and coincides with p53 
upregulation. Indeed, staining for the tumour suppressor protein p53 showed an 
upregulation and coaggregation in the E2-25K-positive neurons suggesting that these 
neurons are likely to proceed into apoptosis (Levine, 1997). The finding of E2-25K 
localization to polyglutamine aggregates in disease, underlines the importance of E2-
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Figure 3: E2-25K mediates polyglutamine-induced cell death.
Cell death of differentiated SH-SY5Y neuroblastoma cells, as assessed by a cell survival assay 
6 days after transduction. Constructs with 19 or 43 glutamine repeats (Qxx-HTT-GFP) were 
cotransduced with either E2-25K, a truncated Δtail mutant or the full antisense sequence of E2-
25K. Polyglutamine-GFP positive cells were analyzed by flow cytometry for conversion of red-
fluorescent cell death reporter (A; representative FACS analysis). Scatter plots clearly show the 
differential distribution of living cells (lower population) and dead cells (higher population; bright 
red-fluorescent). The bars (B) show the percentage of cell death that was observed under different 
conditions. Q19-HTT-GFP shows the background percentage of cell death due to transduction or 
culturing. Expansion of the polyglutamine repeat to Q43-HTT-GFP gives a marked increase in 
cell death that is not changed by addition of E2-25K. Both Δtail as well as the antisense sequence 
give a significant reduction in the levels of cell death. Statistical analysis by two-way ANOVA 
confirmed that cotransduction of both the Δtail and the antisense E2-25K constructs with Q43-
HTT-GFP caused a pronounced, significant decrease of the cell death compared with Q43-HTT-
GFP with wt E2-25K or mock treated *P<0.05.
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25K for HD and also SCA3 and demonstrates that it is not restricted to our in vitro 
model.
Discussion
We previously showed that NIIs in HD and SCA3 were immunopositive for the 
respective expanded polyglutamine proteins (huntingtin and ataxin 3) as well as for 
ubiquitin and UBB+1 (de Pril et al., 2004). The aberrant UBB+1 protein appeared to 
be present in all inclusions and in addition showed a diffuse cytoplasmic staining 
indicating impaired proteasomal function in the affected neurons (Fischer et al., 2003). 
The ubiquitination machinery is an obvious candidate to promote the degradation 
of aberrant proteins such as expanded polyglutamines or UBB+1. Ubiquitination is 
performed by a cascade of enzymes that activate (E1), conjugate (E2) and ligate (E3) 
ubiquitin to target proteins (Glickman and Ciechanover, 2002; Pickart, 2001). E2 
proteins play an indispensable role in the ubiquitination of proteins that are to be 
degraded and interact specifically with a subset of E3 and target proteins.
The ubiquitin-conjugating enzyme E2-25K was reported to be expressed in all areas 
of the brain with higher levels in the areas that are affected in HD, i.e. the striatum 
and frontal cortex (Kalchman et al., 1996). Interaction of E2-25K with huntingtin, 
as found in a yeast two hybrid screen, was however not affected by repeat length. So 
far there have not been any reports on the influence of this interaction on disease 
and the localization in HD. Furthermore, E2-25K was shown to be involved in Aβ-
mediated neurodegeneration and could play a role in Alzheimer pathogenesis (Song 
et al., 2003). 
Staining of neuronally differentiated cell-lines for E2-25K shows a diffuse cytoplasmic 
localization in all cells. Interestingly, the E2-25K protein coaggregates only in part of 
the polyglutamine inclusions and this appeared to coincide with cell death. Aggregate 
forming cells that go into apoptosis might upregulate E2-25K in an attempt to rid 
the cells of the overload of aberrant proteins resulting in coaggregation in these 
cells. This indicates that E2-25K is an important factor in polyglutamine-induced 
neurodegeneration. It is remarkable that Kalchman et al found no obvious upregulation 
of E2-25K on Western blot of the frontal cortex of HD patients compared to controls, 
despite the relatively high expression in the frontal cortex and striatum of controls 
(Kalchman et al., 1996). However, an upregulation in the remaining neurons might 
be masked by neuronal loss in these areas. 
Here we demonstrate that ubiquitination by E2-25K enhances the aggregate formation 
of expanded polyglutamine proteins. Although we do not find an increase in aggregate 
formation upon addition of E2-25K, both the Δtail mutant as well as antisense E2-
25K give a large decrease in the aggregate load. The lack of increase upon addition 
of E2-25K can be explained by sufficient endogenous protein that is present in these 
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Figure 4: E2-25K colocalizes with the NIIs in HD and SCA3.
Double stainings were performed on paraffin sections of HD patients and SCA3 patients for 
E2-25K (red; middle panel) and 1C2 (green; left panel). Besides cytoplasmic staining, E2-25K 
staining was found in part of the inclusions positive for 1C2 in frontal cortex tissue of juvenile HD 
patients (JHD; A), and HD (B-C; closed arrowheads) as well as the pons of SCA3 (D). However, 
E2-25K does not localize to all the NIIs (C; open arrowhead; HD) and appears to be more prone to 
colocalize with the cytoplasmic aggregates that are found (A-D). p53 staining of HD frontal cortex 
shows colocalization with E2-25K (E) suggesting that there is in fact a link between cell death and 
E2-25K coaggregation in disease. Magnification bar is 50μm. 
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cells, as we did not use a knock-out cell line. It appears that ubiquitination by E2-25K 
is a stimulatory mechanism for aggregate formation in polyglutamine disorders. This 
suggests that ubiquitination is either needed for the translocation to the inclusions or 
indirectly, for the formation of more aggregation prone fragments.
Analysis of cell survival showed that E2-25K mediates polyglutamine-induced cell 
death. For a normal repeat length (Q19) no change in the levels of cell death was 
found upon addition of either E2-25K, the Δtail mutant or the antisense sequence. 
Expansion of the glutamine repeat to Q43 results in an increase in cell death, and 
addition of E2-25K has no effect, which demonstrates that endogenous E2-25K is not 
a limiting factor in either the toxicity or the degradation of polyglutamine fragments in 
the cell. However, addition of either the Δtail mutant or the antisense sequence results 
in a drop of toxicity to background levels. The Δtail mutant that lacks its functional 
domain for polyubiquitination will still interact with E1 and accept the activated 
ubiquitin but will no longer transfer the ubiquitin molecule to target proteins like 
huntingtin (Haldeman et al., 1997). Apparently this mutant has a similar dominant 
negative effect on ubiquitination, as does the knock-down of E2-25K by use of the full 
antisense sequence. These results show that ubiquitination of E2-25K targets does not 
only influence the aggregate formation of expanded polyglutamine proteins but more 
importantly triggers polyglutamine-induced cell death. Ubiquitination supposedly 
results in the targeting of the expanded polyglutamines to the proteasome, resulting 
in either proteasome impairment or the formation of toxic fragments. 
Staining of post mortem brain material of both HD and SCA3 for E2-25K showed that 
here as well, a differential staining is found between the NIIs. Although we do find 
staining of aggregates in both disorders and all patients examined, not all aggregates 
are immunopositive for E2-25K. These results are in agreement with our finding in 
neuronally differentiated cell lines where E2-25K preferentially coaggregates with 
expanded polyglutamine proteins in apoptotic cells (Figure 1). E2-25K thus appears 
to indicate the disease state of the respective neurons. Colocalization of E2-25K seems 
to coincide with polyglutamine-induced neuronal death, which occurs both in HD as 
well as in SCA3 (Munoz et al., 2002; Vonsattel et al., 1985). 
The relevance of ubiquitination is furthermore demonstrated by the general finding 
of ubiquitin immunoreactivity in the neuropathological hallmarks of numerous 
neurodegenerative diseases including HD and SCA3 (DiFiglia et al., 1997; Paulson 
et al., 1997). In addition, we have shown for aberrant ubiquitin (UBB+1) that it is 
necessary to ubiquitinate this protein to be translocated to the inclusions, since a 
mutant that lacks the lysine moieties at positions 29 and 48 of the ubiquitin molecule 
does not coaggregate and is no longer toxic (de Pril et al., 2004). Mutating the lysine 
residues at positions 6, 9 and 15 in a truncated fragment of huntingtin similarly 
reduces neuropathology (Steffan et al., 2004).
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Figure 5: Model for targeting of expanded polyglutamines by differential ubiquitination.
Ubiquitination of proteins can play different roles in polyglutamine diseases directly or indirectly 
affecting polyglutamine toxicity. The ubiquitin conjugation by a certain set of E2 and E3 is 
proposed to regulate the position of ubiquitin attachment to the target protein and the ubiquitin 
lysine linkage. Their role in one of these pathways can explain the differences that are found 
between all ubiquitination proteins that have been described for involvement in polyglutamine 
pathology (Table 1). Role 1: Ubiquitination results in targeting of the aberrant proteins to the 
proteasome where they are properly degraded. Role 2: Ubiquitination results in proteasomal 
targeting but inefficient degradation of aberrant proteins, causing either impairment of the UPS 
or the formation of more toxic fragments. Role 3: Ubiquitination is followed by transport of the 
expanded polyglutamine proteins to inclusions as a non-toxic storage for aberrant proteins. 
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We propose here that ubiquitination of proteins plays different roles in polyglutamine 
diseases directly or indirectly affecting polyglutamine toxicity (Figure 5). The 
best known function for ubiquitination is targeting of the aberrant proteins to the 
proteasome where they are properly degraded. The second possibility is proteasomal 
targeting but inefficient degradation of aberrant proteins, causing impairment 
of the UPS or the formation of more toxic fragments. The third option is a role in 
transporting the expanded polyglutamine proteins to inclusions as a non-toxic storage 
for aberrant proteins. Indeed, ubiquitination has different effects on polyglutamine-
induced pathology and toxicity depending on the ubiquitination enzyme that is 
targeted (Table 1). For example, E4B, a mammalian chain assembly factor (E3), is 
required to degrade the expanded form of ataxin 3 and is able to prevent aggregate 
formation of polyglutamines and even neurodegeneration in a Drosophila model of 
SCA3 (Matsumoto et al., 2004). In contrast, mutation of E6-AP (Ube3a), an ubiquitin 
ligase (E3), was shown to aggravate the Purkinje cell pathology in SCA1 transgenic 
mice but to reduce the number of NIIs (Cummings et al., 1999). 
This synopsis recapitulates many different mechanisms that are involved in the 
cellular digestion of polyglutamine proteins (Table 1). The formation of different 
ubiquitin trees by linkage to another ubiquitin lysine (K6, 29, 48 or 63) will result 
in a different cascade, i.e. transport to the proteasome or to inclusions (Pickart and 
Fushman, 2004). The specificity of ubiquitin binding proteins for a certain ubiquitin 
chain linkage will eventually define the translocation of the target proteins (Verma et 
al., 2004). The location of ubiquitin attachment on expanded polyglutamines or other 
target proteins itself might influence the recognition and binding to the proteasome 
and thereby the subsequent degradation. The specific transport of aberrant proteins 
to non-toxic inclusions making use of the cytoskeleton also implies specific targeting 
to these inclusions and is likely to be regulated by ubiquitination (Taylor et al., 2003). 
Cells are accordingly protected from higher levels of free polyglutamine proteins that 
would have a higher probability to interfere with cellular processes eventually resulting 
in neuronal death (Arrasate et al., 2004). We propose that E2-25K is involved in the 
second pathway, whereby the unfavourable formation of ubiquitin trees results in an 
increase in either proteasome impairment or the formation of toxic fragments.
Our results demonstrate that E2-25K is a contributing factor in mediating aggregate 
formation and cell death. These findings illustrate the importance of ubiquitination 
for the cellular clearance or storage of toxic proteins that extends beyond the 
proteasome itself. The reduced toxicity of expanded polyglutamines in the absence 
of functional E2-25K makes it an attractive target in polyglutamine diseases. A small 
ubiquitin-like modifier (SUMO; a post-translational modifier) has recently been 
shown to modify E2-25K (Pichler et al., 2005), impairing ubiquitin chain formation 
by interfering with E1 interaction, making SUMO an interesting molecule to use for 
gene therapy. Interference with SUMOylation has already been shown to enhance 
neurodegeneration in a Drosophila polyglutamine model (Chan et al., 2002), which 
could be linked to E2-25K. Controversially however, reduction of SUMOylation has 
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Table 1: Ubiquitination and polyQ toxicity.
Gene LOF /overexpression Enzyme Aggregation Toxicity Role References
UBC LOF Ub + N.D. 1,2,3 (Nollen et al., 2004)
Uba1 LOF E1 + N.D. 1,2,3 (Nollen et al., 2004)
E2-25K LOF E2 - - 2 this paper
UbcE2D2 LOF E2 N.D. + 1/3 (Fernandez-Funez et al., 2000)
Ubc2EH LOF E2 N.D. + 1/3 (Fernandez-Funez et al., 2000)
Cdc34 LOF E2 - + 3 (Saudou et al., 1998)
Ube3a LOF E3 - + 3 (Cummings et al., 1999)
E4B LOF E3 + N.D. 1/2 (Matsumoto et al., 2004)
E4B overexpression E3 - - 1 (Matsumoto et al., 2004)
CHIP overexpression E3 - - 1 (Jana et al., 2005)
Parkin overexpression E3 - - 1 (Tsai et al., 2003)
UCH-L3 LOF DUB N.D. + 2 (Fernandez-Funez et al., 2000)
Ataxin-3 overexpression DUB - - 2 (Warrick et al., 2005)
UCH-L8 LOF DUB + N.D. 3 (Nollen et al., 2004)
Overview of the involvement of ubiquitination enzymes in polyglutamine aggregation and 
toxicity. Numerous studies have been conducted on the influence of a loss-of-function (LOF) or 
overexpression of ubiquitination enzymes in polyglutamine models. Indicated is the influence 
of the respective change in expression on the polyglutamine aggregation and toxicity. Related 
enzymes appear to result distinctly in an increase (+) or decrease (-) of aggregate formation and 
toxicity. Their influence on these processes implicates the ubiquitination enzymes in either of three 
different pathways: (1) Proteasomal targeting followed by proper degradation of polyglutamine 
fragments. (2) Proteasomal targeting resulting in either UPS impairment or the formation of 
more toxic fragments. (3) Formation of innocuous inclusions. See also Figure 5 for a schematic 
representation.
N.D.: not determined 
DUB: de-ubiquitination enzyme 
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been shown to reduce pathology in another Drosophila polyglutamine model, and in 
cell-lines expression of SUMO accelerates polyglutamine-induced cell death (Steffan 
et al., 2004; Terashima et al., 2002). 
The UPS remains an attractive candidate for therapy in polyglutamine diseases and 
other neurodegenerative disorders. Shifting the balance from UPS impairment and 
formation of toxic fragments to harmless inclusions and efficient degradation would 
be a promising avenue in solving these severe diseases.
Materials and Methods
Transduction
Polyglutamine plasmids containing a truncated huntingtin fragment with different 
polyglutamine repeats (19 and 43) flanked by a HA tag and green fluorescent protein 
(GFP) reporter sequence were provided by Dr. de Cristofaro (de Cristofaro et al., 
1999). E2-25K, E2-25K-Δtail and E2-25K-antisense constructs were identical to those 
described by Song et al. (Song et al., 2003).
cDNAs for HA-Q19-HTT-GFP, HA-Q43-HTT-GFP, E2-25K, E2-25K-Δtail and E2-
25K-antisense, were cloned in the lentiviral transfer plasmid pRRLsin-PPThCMV-
GFP-pre (Naldini et al., 1996). VSV-G pseudotyped lentivirus was produced by 
cotransfection of the transfer plasmid and helper plasmids (pCMVdeltaR8.74 and 
pMD.G.2) in 293T cells. Medium was harvested 24 h after transfection and concentrated 
by ultracentrifugation. Virus pellets were resuspended in PBS containing 0.5% bovine 
serum albumin (Sigma). Stocks were titered with a HIV-1 p24 coat protein ELISA 
(NEN Research, Boston, USA). Lentiviral vectors were used to infect SH-SY5Y 
neuroblastoma cells at a multiplicity of infection of 50. 
Cell lines
Human SH-SY5Y neuroblastoma cells (ATCC:CRL-2260) were cultured in high-
glucose Dulbecco’s modified Eagle medium containing 15% fetal calf serum, 
supplemented with 100 U/ml penicillin and 100 μg/ml streptomycin (all Invitrogen). 
Cells were cultured in 6-well plates (Nunc) 1 day before transduction with addition of 
4 μM all-trans retinoic acid (Sigma) for differentiation. 
Immunocytochemistry
Cells were cultured on collagen-coated glass coverslips and subjected to a Live-
Dead® assay (red fluorescence; Molecular Probes, Leiden, The Netherlands) 4 days 
after transfection. Cells were subsequently fixed and stained for E2-25K (1:400) and 
visualized with donkey-anti-rabbit-Cy5 (1:200; Jackson laboratories). After staining 
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for E2-25K, pictures were obtained using a confocal laser scanning microscope (Zeiss 
510). 
Quantification of cells
For aggregate formation, cells were counted manually at different time intervals after 
transduction. The number of aggregate forming cells was quantified in three randomly 
selected fields per experiment. Experiments were performed in triplicate and statistics 
was performed using three-way ANOVA, testing the interaction between repeat 
expansion, E2-25K protein expression and time course. 
Cell survival assay
We assessed SH-SY5Y cell death using a Live-Dead® kit (red fluorescence; Molecular 
Probes, Leiden, The Netherlands) and analyzed on a flow cytometer (Becton 
Dickinson, Palo Alto, USA) according to the manufacturer’s protocol. In short, we 
harvested lentivirally transduced cells (see before) 6 days after transduction, washed 
them in PBS and incubated them for 30 minutes with the fluorescent reactive dye. 
Subsequently, we fixed cells with 4% formaldehyde for 15 minutes and resuspended in 
PBS-BSA (1x PBS pH-7.6, 0.5% BSA, 0.1% NaN3). We analyzed polyglutamine-GFP 
expressing cells by flow cytometry for conversion of the Live-Dead® kit reactive dye. 
At least 104 polyglutamine-GFP positive cells were examined per sample. Dead cells 
showed a marked increase of red-fluorescence over living cells due to conversion of 
the dye (Figure 3A). Experiments were performed in triplicate and statistics were done 
using two-way ANOVA, testing the interaction between E2-25K protein expression 
and repeat expansion.
Human post-mortem tissue
Autopsy material was obtained from the Huntington bank (Leiden University 
Medical Center, The Netherlands) for HD cases, and the Laboratory of Pathology 
East Netherlands (Enschede, The Netherlands) and University Hospital Groningen 
(Groningen, The Netherlands) for SCA cases (for details see Table 1 of (de Pril et al., 
2004)). We analyzed striatal tissue from 4 different HD patients and frontal cortex 
tissue of in total 30 HD patients with polyglutamine expansion of various lengths. 
Furthermore, we examined the hippocampus, pons, mesencephalon and medulla 
oblongata of 7 different SCA3 patients. All brain areas were fixed in formaldehyde 
and subsequently embedded in paraffin.
Immunohistochemistry
For double stainings, we subjected paraffin sections (6 µm) to irradiation with a broad 
spectrum lamp for at least 24 hours to reduce autofluorescence (Hol et al., 2003; 
Neumann and Gabel, 2002). We then deparaffinized sections and incubated them with 
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the first antibodies overnight in a humid chamber at 4°C. We used 1C2 monoclonal 
antibody against expanded polyglutamine repeats (Trottier et al., 1995) (1:10,000; 
Chemicon, Temecula, USA) monoclonal p53 (1:400; Chemicon) and E2-25K (1:400; 
Affinity) antibody. We enhanced the E2-25K signal using the avidin-biotin-complex 
and tyramine procedure (Kerstens et al., 1995) (Sigma-Aldrich, St.Louis, USA) and 
stained with streptavidin-conjugated-Cy5 (Jackson Laboratories, West Grove, USA). 
1C2 and p53 were directly visualized using donkey-anti-mouse-Cy2. Signal specificity 
was demonstrated by swapping fluorescent dyes and omission of primary antibodies 
to exclude aspecific staining or signal enhancement. Images were obtained using a 
confocal laser scanning microscope (Zeiss 510).
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Frameshift mutations in short repetitive motifs such as GAGAG (ΔGU, ΔGA) during 
mRNA transcription were originally discovered in the rat vasopressin gene (Evans 
et al., 1994). The consecutive search for potential genes that are affected by this 
frameshift resulted in the identification of amyloid precursor protein and ubiquitin-B 
as targets of what was dubbed “molecular misreading” (van den Hurk et al., 2001; 
van Leeuwen et al., 1998). Not only aberrant transcripts for both genes were detected 
but also the resulting proteins were detected in the brains of Alzheimer Disease 
(AD) and Down Syndrome (DS) patients. The localization of these aberrant proteins 
specifically in the neuritic plaques, neuropil threads and tangles, charisteristic of AD 
pathology pointed towards an involvement in disease progression. Subsequent studies 
demonstrated that UBB+1 inhibits the proteasome and can potentially worsen disease 
development (Chapter 3 and (van Tijn et al., 2007)). Although UBB+1 can be degraded 
at low concentrations it was shown to be a marker for proteasomal inhibition most 
likely following the accumulation of disease-related proteins or ageing (Carrard et al., 
2002; Fischer et al., 2003; Keck et al., 2003; Keller et al., 2000; Zhou et al., 2003). In 
synucleopathies and control subjects, in which impairment of the proteasome has not 
been consistently demonstrated, the transcript was detected but the aberrant protein 
was apparently degraded (Fischer et al., 2003; Furukawa et al., 2002). Lentiviral 
injection of UBB+1 constructs in rat brains indeed confirmed that healthy neurons 
are capable of degrading the protein without obvious detrimental effects (Fischer 
et al., 2003). Interestingly, UBB+1 transgenic mice – with a low, constitutive level of 
proteasomal inhibition – do not develop an overt neurological phenotype but only show 
mild defects in contextual memory (Fischer et al., 2009). These findings corroborate 
that expression of UBB+1 alone is not sufficient to cause disease at the low levels of 
misreading that are detected in humans but merely contributes to development and 
course thereof after initial onset (Gerez et al., 2005). 
In two independent UBB+1 transgenic mouse lines several proteins were found to 
be differentially expressed that are also changed in AD brain or transgenic models 
(Fischer et al., 2009). These findings support the idea that the proteasome is inhibited 
in AD, potentially resulting in a dysregulation of energy metabolism (Salehi and 
Swaab, 1999). Altogether, this underlines the importance of efficient proteasomal 
degradation for neurodegenerative diseases such as AD for maintaining normal 
protein levels within the cell. It is conceivable that the accumulation of UBB+1 is 
caused by a failing protein quality control system under neurodegenerative conditions. 
Although UBB+1 is normally tagged by ubiquitin, the subsequent degradation by the 
proteasome is apparently failing within these neurons. The minor extension of the 
C-terminus of the UBB+1 protein potentially results in a difficult substrate for entry 
into the proteasome (Verhoef et al., 2009). Although ubiquitin chains have been shown 
to effectively activate opening of the proteasome the short C-terminal extension 
could still cause an intrinsic hurdle for degradation (Peth et al., 2009). However, the 
specific accumulation of UBB+1 in many neurodegenerative disorders with impaired 
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proteasome function marks this very protein as an indicator as well as a potential 
contributor for neurodegeneration.
The UPS in neurodegeneration
The UPS is responsible for the foremost degradation of cellular proteins that are 
aberrant, become redundant or are under regulatory turnover. Ubiquitination 
is performed by a cascade of enzymes that activate (E1), conjugate (E2) and ligate 
(E3) ubiquitin to target proteins (Glickman and Ciechanover, 2002; Pickart, 2001). 
Ubiquitin functions in tagging proteins for different pathways including proteolytic 
processing and endocytosis. Multi-ubiquitination by K48 or K29 ubiquitin chains 
tag the protein for degradation by the proteasome. The ubiquitin chain binds to 
the 19S part of the proteasome which contains de-ubuiquination activity (DUB) 
resulting in recycling of ubiquitin, and chaperone activity, which results in unfolding 
of the proteasome substrate. The unfolded protein is released into the 20S core for 
proteolytic processing by the tryptic, chymotryptic and PGPH-like activities. Small 
peptides exit the proteasome for further processing by proteases and recycling of the 
resulting amino acids. Efficient degradation of proteins by the UPS is essential for 
normal cellular homeostasis and ridding the cell of aberrant proteins. 
The UPS has been implicated in several neurodegenerative disorders as either the 
primary cause or showing consequential inhibition (Ciechanover and Brundin, 
2003). Many of these disorders including Parkinson Disease (PD), AD and the 
polyglutamine diseases manifest themselves at later stages in life. The activity of the 
UPS has been shown to decrease upon ageing and could thus contribute to the late 
onset of neurodegeneration (Carrard et al., 2002). Aberrant - disease associated - 
proteins can be degraded by an efficient functioning UPS but start to accumulate once 
this system starts to deteriorate (Zhou et al., 2003). Especially polyglutamine diseases 
are characterized by life-long expression of an aberrant protein from a mutant allele. 
The mostly adult age-at-onset of these disorders suggests a gradual buildup of toxic 
proteins or alternatively a gradual deterioration of the degradation machinery of these 
proteins over time as the explanation for the late onset.
The UPS in Huntington Disease
Huntington Disease (HD) and other polyglutamine diseases are characterized by the 
pathological gain of function of an expanded repeat beyond a threshold of around 
36 glutamines. All polyglutamine disorders are characterized by degeneration of 
specific neuronal subtypes based on expression levels and potentially the function of 
the respective proteins. Repeat expansion in structurally distinct proteins results in 
similar aggregation-prone proteins that affect normal cellular function by interfering 
with transcription and transport processes. Neuronal Intranuclear Inclusions (NII) 
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containing at least part of the expanded polyglutamine protein are a common finding 
among these diseases and contain several chaperone proteins including heat-shock 
proteins and components of the UPS. 
Polyglutamine proteins are targeted to the proteasome by ubiquitination and can 
be efficiently degraded (Michalik and Van Broeckhoven, 2004). However, NIIs have 
been shown to contain ubiquitin or ubiquitinated proteins suggesting a failure of the 
proteasome to degrade all expanded polyglutamine protein rather than a failure of 
the ubiquitination machinery (DiFiglia et al., 1997). In addition, components of the 
proteasome have been detected in NIIs in HD and SCA3 (Chapter 1; Figure 6 (Chai 
et al., 1999; Schmidt et al., 2002)). Although expanded polyglutamine repeats can be 
degraded by the proteasome they have been shown to directly inhibit the proteasome 
(Bence et al., 2001; Chai et al., 1999; Verhoef et al., 2002). The repetitive sequence 
is potentially difficult to unfold for insertion into the 20S core and subsequent 
proteolytic processing might be inefficient within this sequence (Holmberg et al., 
2004; Venkatraman et al., 2004). As a result the targeting to the proteasome is causing 
inhibition of the proteasome which instigates a further upregulation of aberrant and 
other cellular proteins that need to be degraded. Consequently, the proteasomal 
inhibition results in a deregulation of cellular protein levels causing disruption of 
normal processes within the respective neurons. Mutating the lysine residues at 
positions 6, 9 and 15 in a truncated fragment of huntingtin reduces proteasomal 
targeting and corresponding neuropathology (Steffan et al., 2004). Similarly, 
ubiquitination of UBB+1 at lysine 29 or 48 is required for its proteasomal inhibition 
and toxicity (Chapter 3 and (van Tijn et al., 2007)). A schematic representation of the 
mechanisms involved in proteasomal inhibition resulting in neuronal dysfunction is 
given in Figure 1. These findings demonstrate the essential function of the proteasome 
in maintaining protein levels below a toxic threshold. An increasing burden of aberrant 
proteins or decline in efficiency of the UPS can result in accumulation of these and 
other proteins. Decreasing the proteasomal targeting of these proteins relieves their 
inhibitory effect on the 26S proteasome. 
In the R6/2 mice, an accumulation of different proteasome reporters was not detected 
despite the high expression levels of Htt exon-1 with 144 glutamine repeat (Bett et al., 
2009; Maynard et al., 2009). However, an accumulation of large ubiquitin conjugates 
was detected in these mice suggesting inefficient degradation (Bennett et al., 2007). 
Interestingly, UPS impairment is detected upon acute expression of expanded Htt 
suggesting activation of compensatory mechanisms in the R6/2 model due to 
high mutant Htt expression throughout life (Ortega et al., 2010). In HD, similar 
compensatory mechanisms might be able to cope with the aberrant protein at early 
age but gradual decline of the UPS or other mechanisms could eventually result in Htt 
accumulation and corresponding neurodegeneration. 
In HD patients, a reduction in proteasome activity was observed in all affected brain 

























































































































































































































































































































































































































































































































































































































































































































































2004). Expanded Htt leads to the accumulation of substrate proteins that are targeted 
for proteasomal degradation showing evidence of UPS inhibition in HD (Bennett et 
al., 2007). It is likely that Htt is ubiquitinated and binds to the proteasome but the 
nature of this kind of substrate makes is difficult to unfold and degrade. Consequently, 
this will result in inhibition of the proteasome and bound substrates could account for 
the inability to reactivate these proteasomes. 
Toxicity and neurodegeneration
As discussed in Chapter 1, the precise nature of specific neuronal dysfunction is still 
unclear but at least in part caused by the gain of function of the polyglutamine repeat. 
Inefficient degradation of these proteins results in increased levels of aggregation 
prone proteins that potentially interfere with other cellular functions. To date it is 
unclear which aggregation state of the protein is causing toxicity but either single 
misfolded protein or small complexes are more likely to interfere with other cellular 
processes. Inclusion bodies (IB) have been shown to function as protective storage 
sites for expanded proteins resulting in decreased levels of aggregation intermediates 
(Arrasate et al., 2004; Ortega et al., 2010). As a result of IB formation the activity 
of the proteasome is restored suggesting efficient recruitment of polyglutamine 
proteins (Mitra et al., 2009). Clearly, this points towards aggregation intermediates 
as the cause of polyglutamine-induced toxicity. Either single misfolded molecules or 
soluble aggregating multimers interfere with cellular processes including proteasomal 
degradation, transcription and transport.
UBB+1 accumulation
In line with other neurodegenerative disorders where proteasome inhibition was 
reported we detected accumulation of UBB+1 in HD and SCA3 (Chapter 3). UBB+1 
accumulates in the cytoplasm and locates to the NII potentially as a result of association 
with proteasome components that are present in NIIs (Chapter 1: Figure 6) (Chai et al., 
1999; Schmidt et al., 2002). Polyubiquitin, binding to the S6a subunit of the 19S cap, 
but lacking processing through the 20S core, potentially causes the UBB+1 resistance 
to degradation and its proteasomal impairment (Lam et al., 2002). Ubiquitination 
on lysine 29 or 48 is required for degradation of UBB+1 as well as its translocation to 
the inclusions (Chapter 3 and (Lindsten and Dantuma, 2003)). In SCA6 we did not 
detect UBB+1 accumulation, pointing towards either efficient degradation or lack of 
accumulation of this kind of aberrant proteins (Chapter 3). SCA6 contains a shorter 
repeat expansion supposedly disturbing the normal function of the α1A calcium 
channel subunit, i.e. loss of function, in contrast to the gain of function of the other 
disorders. Proteasome inhibition has not been implicated in disease development in this 
channelopathy and the cytoplasmic inclusions are not ubiquitinated (Ishikawa et al., 
1999). This demonstrates that colocalization of UBB+1 with polyglutamine proteins is 
dependent on the proteasomal impairment and not on the inclusion formation per se. 
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Synergistic effect of UBB+1
Within a cellular model for HD we demonstrated that addition of UBB+1 results in 
an increase in aggregate formation and polyglutamine induced toxicity (Chapter 3). 
UBB+1 itself is toxic when expressed at high levels and we clearly detected a synergistic 
increase in toxicity. Potentially, the additional proteasomal inhibition by UBB+1 results 
in increased levels of expanded Htt which is not efficiently degraded. These increased 
levels of aggregation prone or fibrillar Htt are causing increased aggregate formation 
in parallel to toxicity. Within the brain of HD and SCA3 patients it is likely that an 
additional inhibition of the UPS aggravates disease development as the machinery is no 
longer able to degrade the aberrant proteins. Differences in UPS efficiency or the level 
at which aberrant proteins like UBB+1 accumulate could account for the inter-patient 
variation in disease onset or extent of atrophy of HD (McNeil et al., 1997; Wexler et 
al., 2004; Zhou et al., 2003). Proteasomal targeting of UBB+1 through ubiquitination is 
thereby required for its proteasomal inhibition, toxicity and contribution to aggregate 
formation and polyglutamine-induced cell death (Chapter 3 and 4 and (De Vrij et al., 
2001; Lindsten et al., 2002)). 
In the cerebral cortex of UBB+1 transgenic mice only a mild inhibition of the 
proteasome was detected as a result of the transgene expression (Fischer et al., 2009). 
Accordingly only mild phenotypic defects were found even in aged mice. Expression 
of expanded Htt in these UBB+1 transgenic mice did however result in a significant 
increase in aggregate formation compared to wild-type littermates (Chapter 4). The 
mild UPS inhibition in the transgenic mice results in increased accumulation of 
Htt and consequential aggregate formation. In vitro we detected an accompanying 
increase of polyglutamine induced toxicity which can potentially be extrapolated to 
the in vivo situation in mice and humans. Several studies have pointed at the protective 
role of inclusion bodies in polyglutamine diseases presumably by efficient storage of 
the aggregation prone proteins (Arrasate et al., 2004; Ortega et al., 2010). Strikingly, 
we detected a marked increase in the formation of multiple aggregates within the 
transgenic mice which points at a deregulation in the formation of the inclusions. 
Protective formation of inclusion bodies is likely to be contained at a single site which 
minimizes additional interactions. Supposedly, the UPS is the primary system for 
degradation of aberrant proteins and we indeed find that proteasomal inhibition by 
UBB+1 clearly contributes to accumulation of expanded Htt. 
Function of E2-25K in HD
E2-25K or Hip2 is an ubiquitin conjugating enzyme that has been shown to interact 
with Htt and in addition mediates Aβ-induced toxicity (Kalchman et al., 1996; 
Song et al., 2003). Either anti-sense or dominant negative E2 constructs lacking the 
catalytic tail domain increase polyglutamine-induced toxicity and aggregation. We 
did not show an increased ubiquitination by E2-25K of Htt and can thus not exclude 
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an indirect effect of E2-25K inactivation on toxicity (Chapter 5). However, the 
accompanying increase in aggregate formation points towards decreased degradation 
of Htt that results in the deterioration. Furthermore, the direct interaction between 
Htt and E2-25K as well as higher expression levels in the striatum and frontal cortex 
suggests a direct effect of E2-25K on Htt (Kalchman et al., 1996). We did not detect a 
further increase in Htt aggregation or toxicity upon addition of UBB+1 which points 
towards a differential effect of both E2-25K and UBB+1 (data not shown). Specifically, 
UBB+1 is thought to directly inhibit the proteasome itself whereas E2-25K affects 
ubiquitination of substrate proteins. An indirect inhibition of the proteasome and not 
the UPS as a whole by E2-25K would potentially result in an additive effect of UBB+1 
on Htt induced toxicity. 
It appears that ubiquitination of E2-25K-targets influences the aggregate formation 
of expanded polyglutamine proteins but more importantly triggers polyglutamine-
induced cell death. Ubiquitination supposedly results in the targeting of the expanded 
polyglutamines to the proteasome, resulting in either proteasome impairment or the 
formation of toxic aggregation prone fragments. Interestingly, E2-25K showed a 
differential staining between NIIs in post mortem brain material of HD and SCA3 and 
in neuronally differentiated cell lines (Chapter 5). It appears that E2-25K preferentially 
coaggregates with expanded polyglutamine proteins in apoptotic cells. Colocalization 
of E2-25K and polyglutamine protein potentially coincides with polyglutamine-
induced neuronal death, which occurs both in HD as well as in SCA3 (Munoz et 
al., 2002; Vonsattel et al., 1985). Consequently, E2-25K might be upregulated or 
alternatively activated upon cellular stress that precedes apoptosis in these neuronal 
cells. In AD, colocalization was found of UBB+1 with E2-25K in the cerebral cortex 
(Song et al., 2003). Furthermore, functional E2-25K was required for UBB+1 induced 
toxicity in a cellular model. Altogether, these results could alternatively indicate that 
ubiquitination by E2-25K has a pro-apoptotic function that is activated upon severe 
proteasomal impairment.
Other UPS components 
The UPS is widely implicated in neurodegenerative disorders either through mutations 
in components of this system or consequential inhibition (Ciechanover and Brundin, 
2003). Mutations in parkin – an E3 ubiquitin ligase – are responsible for autosomal 
dominant PD (Kitada et al., 1998). Interestingly, overexpression of parkin decreased 
toxicity of polyglutamine expanded Atxn3 by direct interaction with the expanded 
polyglutamine protein and the proteasome (Tsai et al., 2003). This interaction 
potentially facilitates degradation of expanded polyglutamine proteins and was shown 
to result in decreased inhibition of the proteasome. Atxn3 itself is a de-ubiquitinating 
enzyme which decreases aggregation and toxicity of polyglutamine proteins (Warrick 
et al., 2005). The mammalian chain assembly factor E4B, is required to degrade the 
expanded form of Atxn3 and is able to prevent aggregate formation of polyglutamines 
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and even neurodegeneration in a Drosophila model of SCA3 (Matsumoto et al., 2004). 
In contrast, mutation of the ubiquitin ligase E6-AP (Ube3a), aggravates the Purkinje 
cell pathology in SCA1 transgenic mice but reduces the number of NIIs (Cummings 
et al., 1999). 
Although the proteins responsible for degradation of mutant Htt have still to be 
determined, several proteins were shown to influence Htt aggregation and toxicity. 
Knock-down or dominant negative E2-25K resulted in reduced aggregation and 
toxicity (Chapter 5). A dominant negative Cdc34, another ubiquitin conjugating 
enzyme, reduced aggregate formation resulting in increased toxicity (Saudou et al., 
1998). Overexpression of the ubiquitin ligase Hrd1 increases ubiquitination and 
consecutive degradation of mutant Htt (Yang et al., 2007). CHIP, another chain 
elongation enzyme, increases ubiquitination and decreases aggregation, resulting in 
improved survival (Jana et al., 2005). Altogether, these differences indicate diverse 
functions of ubiquitination on the same Htt protein resulting in respective signaling 
pathways. Potentially, the ubiquitination site on Htt could determine whether the 
substrate can be efficiently unfolded and degraded by the proteasome. Other ubiquitin 
chain linkages like K63 chains can direct the mutant protein into inclusion bodies for 
protective storage. Further studies will be required to investigate the chain specificity 
and whether these proteins influence other substrates or have a direct effect on Htt. 
Potential therapy
In HD, proteasomal inhibition is caused by a genetic mutation that causes impairment 
of the degradation machinery. Consequently, activation of proteolytic processing 
within these cells would be a promising avenue for treating this type of proteinopathies. 
Increased clearance of aggregation prone Htt will prevent the harmful interaction 
between these proteins and other cellular components. Interestingly, impairment of the 
UPS in a Drosophila model of spinobulbar muscular atrophy resulted in a compensatory 
increase in autophagy to rescue aberrant protein-induced neurodegeneration (Pandey 
et al., 2007). Activation of autophagy with known mediators like rapamycin could be 
highly beneficial for polyglutamine disorders (Ravikumar et al., 2004). UPS activation 
could potentially be even more advantageous as this system appears to account for a 
greater extent of physiological degradation of Htt (Li et al., 2010). Whereas to date 
several proteasome inhibitors have even made it to the market, only few activators of 
this pathway are known (Orlowski and Kuhn, 2008). A small-molecule inhibitor of 
Ubiquitin specific protease-14 results in activation of proteasome activity by inhibiting 
de-ubiquitination by Usp14 on the proteasome (Lee et al., 2010). However, mutation 
of Usp14 results in ataxia as a result of abnormal GABAA receptor turnover (Lappe-
Siefke et al., 2009; Wilson et al., 2002). Also pharmacological activation of specific E3 
enzymes would be a promising therapy as several enzymes including CHIP and Hrd1, 
were shown to reduce aggregation and toxicity (Jana et al., 2005; Yang et al., 2007). 
The reduced toxicity of expanded Htt in the absence of functional E2-25K also makes 
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this an attractive target for screening (Chapter 5). Shifting the balance from UPS 
impairment and formation of toxic fragments to harmless inclusions and efficient 
degradation would be a promising avenue in solving these severe diseases.
Several screens have been performed in order to identify modulators of Htt 
aggregation or polyglutamine-induced toxicity. Gene knock-down approaches in cell 
models as well as model organisms have yielded a great deal of insight in the pathways 
that are involved in disease development (Doumanis et al., 2009; Fischer et al., 2008; 
Nollen et al., 2004; Zhang et al., 2010). Target selection and consecutive screening are 
likely to identify new molecules to treat these disorders. Other approaches have used 
compound screens to directly identify disease modifying small molecules (Desai et 
al., 2006; Fecke et al., 2009). Alternatively, specifically preventing expression from the 
mutant allele would avoid the formation of the disease protein. RNAi based methods 
aimed at either the polyglutamine repeat or specific SNPs have identified several 
oligomers that decrease expanded Htt expression (Hu et al., 2009; Miller et al., 2003; 
Pfister et al., 2009; Zhang et al., 2009). Hopefully, over the coming years either of these 
methods will deliver a therapy to treat or alleviate these diseases with high unmet 
need.
Concluding remarks
HD is an autosomal dominant genetic disorder that manifests itself around mid-
life. Despite expression of the expanded polyglutamine protein throughout life the 
symptoms take decades to develop. The UPS is crucial for the degradation of this type 
of aberrant proteins and is impaired in HD brain (Seo et al., 2004). UBB+1 accumulates 
in the cytoplasm and NII in HD and SCA3 but not in SCA6 (Chapter 3). Consequently, 
UBB+1 functions as a reporter for proteasome impairment in these diseases as a result 
of the pathological gain of function of the polyglutamine repeat. UBB+1 is targeted to 
the proteasome and thereby also inhibits proteasomal degradation. Both in a cellular 
model but also in transgenic mice, expression of UBB+1 resulted in an apparent 
increase in polyglutamine aggregation (Chapter 3 and 4). The decreased degradation 
of expanded Htt resulted in a synergistic increase in polyglutamine induced cell-
death. Although UBB+1 is not causing disease it is clearly a contributing factor after 
initial proteasome inhibition by other factors. 
E2-25K is a potential candidate for ubiquitination of mutant Htt and was shown to 
colocalize with UBB+1 in AD (Song et al., 2003). Functional knock-down of E2-25K 
indeed relieved polyglutamine induced aggregation and toxicity (Chapter 5). These 
findings illustrate the importance of ubiquitination for the cellular clearance or 
storage of toxic proteins that extends beyond the proteasome itself. Further research 
is needed to elucidate the sequence of events leading to proteasome inhibition and 
subsequent neuronal dysfunction. Importantly, the present thesis demonstrates the 
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Huntington disease (HD) is the best know of the polyglutamine disorders which 
are caused by the excessive expansion of a CAG repeat in a transcribed gene. It is 
estimated that there are 1300 HD patients in the Netherlands and even more people 
that are currently at risk. Translation of the CAG repeat results in proteins with an 
expanded polyglutamine repeat. Expansion of this repeat above a threshold of 36 
results in an aggregation prone protein leading to disease onset around mid-life. In all 
polyglutamine diseases an inverse correlation is found between repeat expansion and 
age of disease onset. Neuronal intranuclear inclusions (NII) which contain at least 
part of the expanded protein are identified as hallmarks of the polyglutamine diseases. 
Inclusions have been suggested to function as protective storage sites implying that 
soluble misfolded proteins are the primary cause of toxicity. The aggregation prone 
properties of these proteins are causing the pathological gain of function due to 
interference with normal cellular function. 
The ubiquitin proteasome system (UPS) is responsible for the main protein 
degradation within the cell. The UPS contributes to cellular homeostasis by 
regulating the expression of essential proteins and degradation of excessive proteins. 
In addition, the UPS is involved in cellular protein quality control and responsible 
for the degradation of aberrant proteins that accumulate in neurodegeneration. Also 
expanded polyglutamine proteins can be degraded by the UPS in order to protect the 
cell from this aggregation prone protein. However, the expanded repeat is also difficult 
to degrade causing impairment of the proteasome and consequential accumulation. 
The general introduction in Chapter 1 gives an overview of several of the important 
aspects leading to neurodegeneration in HD and specifically the contribution of the 
UPS. 
Chapter 2 describes the discovery of molecular misreading which occurs on GAGAG 
motifs in different genes. The frameshift mutant of ubiquitin B (UBB+1) is formed by a 
dinucleotide deletion (ΔGU) in the mRNA. The mutant ubiquitin protein that is formed 
can no longer ubiquitinate substrate proteins but is a target for ubiquitination and 
subsequent proteasomal degradation. UBB+1 accumulates in several neurodegenerative 
diseases and is an in vivo marker for proteasomal inhibition. 
In Chapter 3, we investigated the accumulation of UBB+1 in HD and Spinocerebellar 
ataxia-3 (SCA3) and potential contribution to neurodegeneration. UBB+1 was found 
to accumulate in the cytoplasm and NII in the affected brain regions of HD and SCA3 
demonstrating in vivo proteasome inhibition in these disorders. In a cellular model 
of HD we observed that UBB+1 results in inhibition of the proteasome which causes 
increased aggregate formation. In addition, a synergistic increase in polyglutamine 
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induced cell death was found upon expression of UBB+1. These findings implicate 
UBB+1 as an aggravating factor in polyglutamine induced neurodegeneration and 
stresses the importance of the UPS for degradation of aberrant polyglutamine and 
UBB+1 proteins.
UBB+1 transgenic mice show a mild inhibition of the proteasome. In Chapter 4 we 
tested the influence of this UPS inhibition by UBB+1 on Htt aggregation in vivo. 
Expression of expanded polyglutamine protein in the striatum of the UBB+1 transgenic 
mice showed a strong increase in NII formation compared to wildtype littermates. 
These results demonstrate in vivo that minor differences in UPS capacity can have 
major detrimental effects on the neuropathology of HD.
The ubiquitin conjugating enzyme E2-25K has been shown to interact directly with 
Htt independent of polyglutamine repeat length. In Chapter 5, we investigated the 
localization of E2-25K in HD as well as the contribution to neurodegeneration. 
E2-25K colocalizes with a subset of NII in HD brain as well as with aggregates in 
apoptotic cells in vitro. Dominant negative E2-25K – lacking the catalytic tail domain 
– as well as an antisense construct decreased aggregate formation of expanded Htt. 
Additionally, mutant and antisense E2-25K reduced polyglutamine-induced cell 
death. These findings show that ubiquitination of E2-25K-targets contributes to 
aggregate formation as well as neuronal cell death in HD. 
Finally, in Chapter 6 the different findings of this thesis are discussed as well as further 
research and perspectives. 
In conclusion, the findings of this thesis illustrate the importance of the UPS for 
the cellular clearance of toxic proteins involved in neurodegeneration. The precise 
mechanism of specific neuronal dysfunction in HD is still unclear but is triggered by 
the gain of function of the polyglutamine repeat. Impairment of the UPS results in the 
further accumulation of aberrant proteins and subsequent neuronal dysfunction. Since 
HD is caused by protein expression from a mutant allele, more efficient degradation 




De ziekte van Huntington (HD) is de meest bekende van de polyglutamine ziektes die 
worden veroorzaakt door de expansie van een CAG herhaling in een getranscribeerd 
gen. In Nederland zijn er naar schatting 1300 patienten met HD en een nog groter 
aantal die het risico lopen de ziekte te ontwikkelen. Translatie van de CAG herhaling 
resulteert in huntingtine eiwit met een verlengde reeks glutamines in de N-terminus. 
Expansie van deze glutamine reeks boven een drempel van 36 resulteert in een 
eiwit dat aggregeert en leidt tot start van de ziekte rond middelbare leeftijd. In alle 
polyglutamine ziektes wordt een omgekeerde correlatie gevonden tussen glutamine 
verlenging en leeftijd bij aanvang van de ziekte. Neuronale intranucleaire inclusies 
(NII) die tenminste een gedeelte van het verlengde eiwit bevatten worden gevonden 
als kenmerk van de polyglutamine ziektes. Van deze inclusies is gesuggereerd dat ze 
functioneren als beschermende opslag terwijl de oplosbare verkeerd gevouwen eiwitten 
de voornaamste reden zouden zijn van de toxiciteit. De afwijkende eiwitvouwing van 
deze eiwitten veroorzaakt de uiteindelijke pathologie door verstoring van het normale 
functioneren van de cel.
Het ubiquitine proteasoom systeem (UPS) is verantwoordelijk voor de voornaamste 
eiwit afbraak binnen de cel. Het UPS draagt bij aan het cellulaire evenwicht door 
de regeling van de expressie van essentiele eiwitten en afbraak van overbodige 
eiwitten. Daarnaast is het UPS betrokken bij de cellulaire kwaliteits controle van 
eiwitten en verantwoordelijk voor de afbraak van foutieve eiwitten die ophopen bij 
neurodegeneratie. Ook verlengde polyglutamine eiwitten kunnen worden afgebroken 
door het UPS om de cel te beschermen tegen dit misgevouwen eiwit. De verlengde 
reeks glutamines is echter moeilijk af te breken wat resulteert in remming van het 
proteasoom en eiwit ophoping als gevolg daarvan.
De algemene introductie in Hoofdstuk 1 geeft een overzicht van verschillende van 
de belangrijke aspecten die leiden tot neurodegeneratie in HD en in het bijzonder de 
bijdrage van het UPS. 
Hoofdstuk 2 beschrijft de ontdekking van moleculaire leesfouten die optreden in 
GAGAG motieven in verschillende genen. De frameshift mutant van ubiquitine 
B (UBB+1) wordt gevormd door een dinucleotide (ΔGU) deletie in het mRNA. 
Het mutant ubiquitine eiwit dat wordt gevormd kan niet langer substraat eiwitten 
ubiquitineren maar is zelf wel een substraat voor ubiquitinatie en daaropvolgende 
proteasomale afbraak. UBB+1 hoopt op bij verschillende neurodegeneratieve ziekten 
en is een in vivo marker voor proteasoom remming.
In Hoofdstuk 3, hebben we de ophoping onderzocht van UBB+1 bij HD en 
spinocerebellaire ataxie-3 (SCA3) en tevens de mogelijke bijdrage aan neurodegeneratie. 
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UBB+1 blijkt op te hopen in het cytoplasma en NII in de aangetaste hersengebieden 
van HD en SCA3 en toont daarmee in vivo aan dat het proteasoom geremd is bij deze 
ziekten. In een cellulair model van HD vonden we dat UBB+1 resulteert in remming 
van het proteasoom wat leidt tot een toename in de vorming van inclusies. Bovendien 
werd een synergistische verhoging van polyglutamine geïnduceerde celdood 
gevonden als gevolg van UBB+1 expressie. Deze bevindingen impliceren dat UBB+1 de 
polyglutamine geïnduceerde neurodegeneratie versterkt en onderstreept het belang 
van het UPS voor de afbraak van misgevouwen polyglutamine en UBB+1 eiwitten.
UBB+1 transgene muizen laten een milde remming van het proteasoom zien. In 
Hoofdstuk 4 hebben we getest wat de invloed is van deze remming van het UPS door 
UBB+1 op de vorming van Htt inclusies in vivo. Expressie van verlengde polyglutamine 
eiwitten in het striatum van UBB+1 transgene muizen toonde een sterke toename in de 
vorming van NII in vergelijking met verwante wildtype muizen. Deze resultaten laten 
in vivo zien dat minimale verschillen in de UPS capaciteit sterke nadelige effecten 
kunnen hebben op de neuropathologie kenmerkend voor HD. 
Van het ubiquitine conjugerende enzym E2-25K is aangetoond dat het een directe 
interactie aangaat met Htt onafhankelijk van de polyglutamine lengte. In Hoofdstuk 
5, hebben we de lokalisatie van E2-25K onderzocht en tevens de bijdrage aan 
neurodegeneratie. E2-25K co-lokaliseert met een gedeelte van de NII in HD hersenen 
en tevens met inclusies in apoptotische cellen in vitro. Dominant negatieve E2-25K – 
zonder het katalytische staart domein – alsook een antisense construct verminderden 
de aggregaat vorming van verlengd Htt. Daarnaast reduceerden de mutant en antisense 
E2-25K constructen de polyglutamine geïnduceerde celdood. Deze bevindingen laten 
zien dat ubiquitinatie van E2-25K substraten bijdraagt aan zowel de inclusie vorming 
als neuronale celdood bij HD.
Tot slot worden in Hoofdstuk 6 de verschillende bevindingen van dit proefschrift 
besproken evenals vervolg onderzoek en toekomst perspectieven.
De bevindingen van dit proefschrift illustreren het belang van het UPS voor de 
cellulaire afbraak van toxische eiwitten die betrokken zijn bij neurodegeneratie. 
Het precieze mechanisme van specifieke neuronale verstoring in HD is nog altijd 
onbekend maar wordt veroorzaakt door de verkregen functie van de polyglutamine 
repeat. Remming van het UPS resulteert in verdere ophoping van foutieve eiwitten 
en uiteindelijk neuronaal disfunctioneren. Doordat HD wordt veroorzaakt door 
eiwit expressie van een mutant allel zou efficiëntere afbraak van of mRNA of eiwit de 
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